≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Benign neoplasm: Prostate

DOID EFO Endpoint Browser PheWeb

CD2_BENIGN_PROSTATE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

only males

226725

2. Check conditions

None

226725

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D29.1&
  • Hospital discharge: ICD-9 — 2222
  • Cause of death: ICD-10 — D29.1&
  • Cause of death: ICD-9 — 2222

2 out of 7 registries used, show all original rules.

247

4. Check minimum number of events

None

247

5. Include endpoints

None

247

6. Filter based on genotype QC (FinnGen only)

240

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D29
Name in latin
Neoplasma benignum prostatae

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1360 - 1360
Only index persons 1120 - 1120
Unadjusted period prevalence (%)
Whole population 0.04 - 0.04
Only index persons 0.04 - 0.04
Median age at first event (years)
Whole population - - 71.01
Only index persons - - 69.61

-FinnGen-

Key figures

All Female Male
Number of individuals 240 - 240
Unadjusted period prevalence (%) 0.11 - 0.11
Median age at first event (years) 68.24 - 68.24

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
247
Matched controls
2470
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D29.1
ICD-10 Finland
Benign neoplasm: Prostate
4503599627370496.0
307.7
244
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
4.9
33.6
115
372
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
4.7
31.3
109
354
NK6AN
NOMESCO Finland
Total body bone isotope imaging
10.1
29.7
36
41
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
8.2
29.0
42
60
ZXC96
NOMESCO Finland
Robot assisted procedure
10.5
29.0
34
37
KEC01
NOMESCO Finland
Percutaneous endoscopic radical prostatectomy
8.5
27.1
38
52
KE1BE
NOMESCO Finland
Rectal ultrasound examinaiton of prostata
3.4
17.2
83
319
116
Kela drug reimbursment
Prostate cancer
3.6
15.3
61
206
XJH00
NOMESCO Finland
Transanal ultrasonography
3.3
12.2
55
199
UKC02
NOMESCO Finland
Cystoscopy
2.5
10.7
94
483
Y77
ICPC
Malignant neoplasm prostate
3.7
10.2
34
101
KE1AT
NOMESCO Finland
Biopsy of prostata with ultrasoudnguidance
2.9
9.8
53
212
XKD00
NOMESCO Finland
Uroflowmetry
2.4
9.5
103
576
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
3.0
9.2
47
182
N40
ICD-10 Finland
Hyperplasia of prostate
2.3
8.8
154
1042
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
2.3
8.1
88
486
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
9.9
7.9
15
16
G04CB01
ATC
finasteride; oral
2.2
7.6
86
482
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.6
7.5
26
79
WW200, ,
SPAT
2.2
7.3
89
512
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.0
6.4
152
1099

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Outpatient Visit
OP [9202]
2.1e-01
3.4e-01
8.1e-01
6.3e+00
1.9e+00
1.3e+00
9.9e-01
cases:76.02%
controls:72.03%
cases:60.98%
controls:52.56%
cases:21.14%
controls:10.61%
cases:68.29%
controls:0.41%
cases:45.53%
controls:11.23%
cases:80.50%
controls:51.97%
cases:92.23%
controls:81.47%
187
1772
59
688
150
1293
96
1167
52
261
194
2199
168
10
78
2450
112
276
134
2181
194
1252
47
1157
178
1596
15
363
Urology
34 [38004474]
3.7e-01
5.9e-01
1.9e+00
—
3.7e+00
2.5e+00
1.9e+00
cases:17.89%
controls:13.05%
cases:11.38%
controls:6.63%
cases:7.32%
controls:1.14%
—
—
cases:31.71%
controls:1.18%
cases:48.13%
controls:6.77%
cases:54.92%
controls:15.98%
44
321
202
2139
28
163
218
2297
18
28
228
2432
—
78
29
168
2428
116
163
125
2246
106
313
87
1646
Hyperplasia of prostate
N40 [45563015]
9.8e-01
1.5e+00
2.0e+00
1.0e+50
2.6e+00
1.6e+00
9.4e-01
cases:23.17%
controls:10.20%
cases:16.67%
controls:4.31%
cases:4.47%
controls:0.65%
cases:6.10%
controls:0.00%
cases:9.35%
controls:0.73%
cases:21.58%
controls:5.06%
cases:30.05%
controls:14.40%
57
251
189
2209
41
106
205
2354
11
16
235
2444
15
0
231
2460
23
18
223
2439
52
122
189
2287
58
282
135
1677
Malignant neoplasm of prostate
C61 [45547509]
-1.1e+00
—
—
—
3.5e+00
2.6e+00
2.5e+00
cases:2.03%
controls:5.73%
—
—
—
—
—
—
cases:23.17%
controls:0.90%
cases:34.44%
controls:3.86%
cases:46.63%
controls:6.43%
5
141
241
2319
—
—
—
57
22
189
2435
83
93
158
2316
90
126
103
1833
Bacteria [Presence] in Urine
87829-8 [36304419]
2.9e-01
1.1e+00
2.3e+00
1.0e+50
2.0e+00
1.3e+00
5.1e-01
cases:6.91%
controls:5.28%
cases:6.50%
controls:2.28%
cases:3.66%
controls:0.37%
cases:2.44%
controls:0.00%
cases:2.44%
controls:0.33%
cases:7.88%
controls:2.24%
cases:9.33%
controls:5.82%
17
130
229
2330
16
56
230
2404
9
9
237
2451
6
0
240
2460
6
8
240
2449
19
54
222
2355
18
114
175
1845
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
8.3e-02
8.0e-01
2.6e+00
1.0e+50
2.1e+00
1.1e+00
4.9e-01
cases:7.72%
controls:7.15%
cases:7.32%
controls:3.41%
cases:5.69%
controls:0.45%
cases:3.25%
controls:0.00%
cases:3.25%
controls:0.41%
cases:8.30%
controls:2.91%
cases:12.95%
controls:8.37%
19
176
227
2284
18
84
228
2376
14
11
232
2449
8
0
238
2460
8
10
238
2447
20
70
221
2339
25
164
168
1795
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
2.7e-01
2.9e-01
8.9e-01
3.7e+00
9.8e-01
3.9e-01
-4.3e-01
cases:20.33%
controls:16.26%
cases:17.48%
controls:13.66%
cases:8.54%
controls:3.70%
cases:7.32%
controls:0.20%
cases:8.54%
controls:3.38%
cases:19.92%
controls:14.40%
cases:19.69%
controls:27.41%
50
400
196
2060
43
336
203
2124
21
91
225
2369
18
5
228
2455
21
83
225
2374
48
347
193
2062
38
537
155
1422
Oncology Clinic/Center
261QX0200X [38004268]
-2.4e-01
1.6e-01
3.3e+00
1.0e+50
—
1.3e+00
8.9e-01
cases:5.69%
controls:7.15%
cases:2.85%
controls:2.44%
cases:7.32%
controls:0.28%
cases:4.07%
controls:0.00%
—
—
cases:8.71%
controls:2.53%
cases:19.17%
controls:8.88%
14
176
232
2284
7
60
239
2400
18
7
228
2453
10
0
236
2460
—
21
61
220
2348
37
174
156
1785
Supplier / Service Provider
OMOP5117446 [33004]
-7.7e-01
1.0e-01
—
—
—
2.6e+00
3.4e+00
cases:12.20%
controls:23.13%
cases:5.28%
controls:4.80%
—
—
—
—
—
—
cases:5.39%
controls:0.42%
cases:21.24%
controls:0.87%
30
569
216
1891
13
118
233
2342
—
—
—
13
10
228
2399
41
17
152
1942
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
3.3e-01
8.7e-01
1.9e+00
1.0e+50
1.6e+00
8.4e-01
5.1e-01
cases:14.63%
controls:10.98%
cases:11.79%
controls:5.33%
cases:6.10%
controls:0.93%
cases:3.25%
controls:0.00%
cases:4.47%
controls:0.98%
cases:12.03%
controls:5.56%
cases:24.87%
controls:16.54%
36
270
210
2190
29
131
217
2329
15
23
231
2437
8
0
238
2460
11
24
235
2433
29
134
212
2275
48
324
145
1635
MCH [Entitic mass]
28539-5 [3035941]
1.2e-01
8.9e-02
7.6e-01
3.6e+00
7.9e-01
1.4e-01
1.1e-01
cases:27.24%
controls:25.00%
cases:23.98%
controls:22.40%
cases:11.79%
controls:5.89%
cases:8.54%
controls:0.24%
cases:11.38%
controls:5.49%
cases:27.39%
controls:24.66%
cases:50.26%
controls:47.58%
67
615
179
1845
59
551
187
1909
29
145
217
2315
21
6
225
2454
28
135
218
2322
66
594
175
1815
97
932
96
1027
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.1e-01
8.7e-02
7.6e-01
3.6e+00
7.9e-01
1.4e-01
1.1e-01
cases:27.24%
controls:25.04%
cases:23.98%
controls:22.44%
cases:11.79%
controls:5.89%
cases:8.54%
controls:0.24%
cases:11.38%
controls:5.49%
cases:27.39%
controls:24.78%
cases:50.26%
controls:47.58%
67
616
179
1844
59
552
187
1908
29
145
217
2315
21
6
225
2454
28
135
218
2322
66
597
175
1812
97
932
96
1027
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.1e-01
8.9e-02
7.6e-01
3.6e+00
7.9e-01
1.4e-01
1.1e-01
cases:27.24%
controls:25.04%
cases:23.98%
controls:22.40%
cases:11.79%
controls:5.89%
cases:8.54%
controls:0.24%
cases:11.38%
controls:5.49%
cases:27.39%
controls:24.74%
cases:50.26%
controls:47.58%
67
616
179
1844
59
551
187
1909
29
145
217
2315
21
6
225
2454
28
135
218
2322
66
596
175
1813
97
932
96
1027
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.3e-01
8.7e-02
7.6e-01
3.6e+00
7.9e-01
1.4e-01
1.1e-01
cases:27.64%
controls:25.08%
cases:23.98%
controls:22.44%
cases:11.79%
controls:5.89%
cases:8.54%
controls:0.24%
cases:11.38%
controls:5.49%
cases:27.39%
controls:24.74%
cases:50.26%
controls:47.63%
68
617
178
1843
59
552
187
1908
29
145
217
2315
21
6
225
2454
28
135
218
2322
66
596
175
1813
97
933
96
1026
Platelets [#/volume] in Blood
26515-7 [3007461]
1.2e-01
8.9e-02
7.6e-01
3.6e+00
7.9e-01
1.4e-01
1.1e-01
cases:27.24%
controls:24.96%
cases:23.98%
controls:22.40%
cases:11.79%
controls:5.89%
cases:8.54%
controls:0.24%
cases:11.38%
controls:5.49%
cases:27.39%
controls:24.66%
cases:50.26%
controls:47.52%
67
614
179
1846
59
551
187
1909
29
145
217
2315
21
6
225
2454
28
135
218
2322
66
594
175
1815
97
931
96
1028
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.1e-01
8.4e-02
7.5e-01
3.6e+00
7.9e-01
1.6e-01
1.1e-01
cases:27.24%
controls:25.12%
cases:23.98%
controls:22.48%
cases:11.79%
controls:5.93%
cases:8.54%
controls:0.24%
cases:11.38%
controls:5.49%
cases:27.80%
controls:24.78%
cases:50.26%
controls:47.58%
67
618
179
1842
59
553
187
1907
29
146
217
2314
21
6
225
2454
28
135
218
2322
67
597
174
1812
97
932
96
1027
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.1e-01
8.4e-02
7.6e-01
3.6e+00
7.8e-01
1.4e-01
1.1e-01
cases:27.24%
controls:25.12%
cases:23.98%
controls:22.48%
cases:11.79%
controls:5.89%
cases:8.54%
controls:0.24%
cases:11.38%
controls:5.54%
cases:27.39%
controls:24.78%
cases:50.26%
controls:47.63%
67
618
179
1842
59
553
187
1907
29
145
217
2315
21
6
225
2454
28
136
218
2321
66
597
175
1812
97
933
96
1026
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
3.8e-01
1.4e+00
2.3e+00
—
—
1.1e+00
3.5e-01
cases:4.47%
controls:3.09%
cases:6.50%
controls:1.75%
cases:2.85%
controls:0.28%
—
—
—
—
cases:6.22%
controls:2.20%
cases:8.81%
controls:6.38%
11
76
235
2384
16
43
230
2417
7
7
239
2453
—
—
15
53
226
2356
17
125
176
1834
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
2.1e-01
2.9e-01
9.4e-01
3.7e+00
8.5e-01
2.7e-01
-7.6e-01
cases:22.76%
controls:19.23%
cases:19.92%
controls:15.65%
cases:9.35%
controls:3.86%
cases:7.32%
controls:0.20%
cases:8.94%
controls:4.03%
cases:21.16%
controls:17.02%
cases:21.76%
controls:37.37%
56
473
190
1987
49
385
197
2075
23
95
223
2365
18
5
228
2455
22
99
224
2358
51
410
190
1999
42
732
151
1227
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
4.1e-01
5.8e-01
2.5e+00
—
2.2e+00
6.9e-01
3.2e-01
cases:6.50%
controls:4.43%
cases:3.66%
controls:2.07%
cases:2.85%
controls:0.24%
—
—
cases:2.85%
controls:0.33%
cases:3.73%
controls:1.91%
cases:6.74%
controls:5.00%
16
109
230
2351
9
51
237
2409
7
6
239
2454
—
7
8
239
2449
9
46
232
2363
13
98
180
1861
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
3.8e-01
1.2e+00
2.2e+00
—
—
1.2e+00
3.6e-01
cases:4.47%
controls:3.09%
cases:5.28%
controls:1.71%
cases:2.44%
controls:0.28%
—
—
—
—
cases:5.81%
controls:1.87%
cases:5.18%
controls:3.68%
11
76
235
2384
13
42
233
2418
6
7
240
2453
—
—
14
45
227
2364
10
72
183
1887
Essential (primary) hypertension
I10 [45591453]
8.8e-02
-3.6e-03
—
4.5e+00
8.5e-01
5.1e-01
3.2e-01
cases:23.58%
controls:22.03%
cases:13.01%
controls:13.05%
—
—
cases:15.04%
controls:0.20%
cases:5.28%
controls:2.32%
cases:21.16%
controls:13.82%
cases:39.38%
controls:32.16%
58
542
188
1918
32
321
214
2139
—
37
5
209
2455
13
57
233
2400
51
333
190
2076
76
630
117
1329
CBC panel - Blood by Automated count
58410-2 [40761511]
3.0e-02
-1.0e-02
8.1e-01
3.3e+00
1.1e+00
-8.5e-02
-2.3e-02
cases:21.14%
controls:20.65%
cases:13.41%
controls:13.54%
cases:6.91%
controls:3.21%
cases:5.28%
controls:0.20%
cases:7.72%
controls:2.60%
cases:14.52%
controls:15.61%
cases:36.27%
controls:36.80%
52
508
194
1952
33
333
213
2127
17
79
229
2381
13
5
233
2455
19
64
227
2393
35
376
206
2033
70
721
123
1238
Laboratory Visit
OMOP4822461 [32036]
8.1e-02
1.0e-01
8.8e-01
3.5e+00
5.9e-01
8.1e-02
3.2e-01
cases:28.46%
controls:26.83%
cases:27.64%
controls:25.65%
cases:21.54%
controls:10.20%
cases:12.20%
controls:0.41%
cases:16.26%
controls:9.69%
cases:30.29%
controls:28.60%
cases:59.59%
controls:51.76%
70
660
176
1800
68
631
178
1829
53
251
193
2209
30
10
216
2450
40
238
206
2219
73
689
168
1720
115
1014
78
945
Leukocytes [#/volume] in Urine
30405-5 [3018095]
1.7e-01
9.1e-01
2.4e+00
1.0e+50
1.6e+00
1.0e+00
2.8e-01
cases:7.72%
controls:6.59%
cases:8.13%
controls:3.46%
cases:4.88%
controls:0.45%
cases:2.85%
controls:0.00%
cases:2.44%
controls:0.49%
cases:9.54%
controls:3.69%
cases:11.40%
controls:8.88%
19
162
227
2298
20
85
226
2375
12
11
234
2449
7
0
239
2460
6
12
240
2445
23
89
218
2320
22
174
171
1785
leuprorelin; implant, parenteral
L02AE02 [21603825]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
2.0e+00
2.0e+00
cases:0.00%
controls:1.71%
cases:0.00%
controls:1.14%
cases:0.00%
controls:0.24%
—
—
cases:0.00%
controls:0.24%
cases:7.88%
controls:1.12%
cases:12.44%
controls:1.94%
0
42
246
2418
0
28
246
2432
0
6
246
2454
—
0
6
246
2451
19
27
222
2382
24
38
169
1921
Malignant neoplasm prostate
Y77 [2002001445]
-1.0e+50
-1.0e+50
—
—
—
2.4e+00
1.5e+00
cases:0.00%
controls:0.93%
cases:0.00%
controls:0.53%
—
—
—
—
—
—
cases:4.98%
controls:0.46%
cases:7.25%
controls:1.74%
0
23
246
2437
0
13
246
2447
—
—
—
12
11
229
2398
14
34
179
1925
bicalutamide; oral
L02BB03 [21603837]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
2.2e+00
1.7e+00
cases:0.00%
controls:0.89%
cases:0.00%
controls:0.77%
cases:0.00%
controls:0.20%
—
—
—
—
cases:4.98%
controls:0.58%
cases:5.70%
controls:1.07%
0
22
246
2438
0
19
246
2441
0
5
246
2455
—
—
12
14
229
2395
11
21
182
1938
FEV1/FVC
19926-5 [3011505]
8.0e-01
1.9e+00
—
—
—
1.8e+00
2.0e+00
cases:4.07%
controls:1.87%
cases:2.85%
controls:0.45%
—
—
—
—
—
—
cases:2.49%
controls:0.42%
cases:6.22%
controls:0.87%
10
46
236
2414
7
11
239
2449
—
—
—
6
10
235
2399
12
17
181
1942
FEV1
20150-9 [3024653]
8.0e-01
1.9e+00
—
—
—
1.8e+00
2.0e+00
cases:4.07%
controls:1.87%
cases:2.85%
controls:0.45%
—
—
—
—
—
—
cases:2.49%
controls:0.42%
cases:6.22%
controls:0.87%
10
46
236
2414
7
11
239
2449
—
—
—
6
10
235
2399
12
17
181
1942
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
8.0e-01
1.9e+00
—
—
—
1.8e+00
2.0e+00
cases:4.07%
controls:1.87%
cases:2.85%
controls:0.45%
—
—
—
—
—
—
cases:2.49%
controls:0.42%
cases:6.22%
controls:0.87%
10
46
236
2414
7
11
239
2449
—
—
—
6
10
235
2399
12
17
181
1942
Transanal ultrasonography
XJH00 [2001305132]
9.7e-01
1.3e+00
—
1.0e+50
—
2.2e+00
1.6e+00
cases:2.85%
controls:1.10%
cases:2.03%
controls:0.57%
—
—
cases:15.85%
controls:0.00%
—
—
cases:4.15%
controls:0.46%
cases:6.22%
controls:1.33%
7
27
239
2433
5
14
241
2446
—
39
0
207
2460
—
10
11
231
2398
12
26
181
1933
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
2.3e-01
8.6e-01
2.7e+00
1.0e+50
1.9e+00
9.7e-01
3.6e-01
cases:6.91%
controls:5.57%
cases:6.10%
controls:2.68%
cases:4.47%
controls:0.33%
cases:2.44%
controls:0.00%
cases:2.44%
controls:0.37%
cases:6.64%
controls:2.62%
cases:8.81%
controls:6.33%
17
137
229
2323
15
66
231
2394
11
8
235
2452
6
0
240
2460
6
9
240
2448
16
63
225
2346
17
124
176
1835
Medical Oncology
90 [38004507]
—
—
—
—
—
2.1e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:17.43%
controls:2.45%
cases:17.10%
controls:4.75%
—
—
—
—
—
42
59
199
2350
33
93
160
1866
Ultrasound measurement of residual urine
KC1EE [2001305918]
2.0e-01
3.6e-01
—
1.0e+50
—
2.4e+00
1.1e+00
cases:4.47%
controls:3.70%
cases:2.03%
controls:1.42%
—
—
cases:2.85%
controls:0.00%
—
—
cases:9.13%
controls:0.87%
cases:12.95%
controls:4.80%
11
91
235
2369
5
35
241
2425
—
7
0
239
2460
—
22
21
219
2388
25
94
168
1865
finasteride; oral
D11AX10 [21602350]
8.1e-01
9.9e-01
1.0e+00
—
7.3e-01
8.7e-01
8.5e-01
cases:13.41%
controls:6.42%
cases:13.01%
controls:5.28%
cases:3.66%
controls:1.38%
—
—
cases:3.25%
controls:1.59%
cases:12.45%
controls:5.65%
cases:17.62%
controls:8.37%
33
158
213
2302
32
130
214
2330
9
34
237
2426
—
8
39
238
2418
30
136
211
2273
34
164
159
1795
finasteride; oral
G04CB01 [21602675]
8.1e-01
9.9e-01
1.0e+00
—
7.3e-01
8.7e-01
8.5e-01
cases:13.41%
controls:6.42%
cases:13.01%
controls:5.28%
cases:3.66%
controls:1.38%
—
—
cases:3.25%
controls:1.59%
cases:12.45%
controls:5.65%
cases:17.62%
controls:8.37%
33
158
213
2302
32
130
214
2330
9
34
237
2426
—
8
39
238
2418
30
136
211
2273
34
164
159
1795
Bacteria identified in Urine by Culture
630-4 [3026008]
2.2e-01
3.0e-01
1.9e+00
—
2.3e+00
1.2e+00
2.6e-01
cases:4.07%
controls:3.29%
cases:3.25%
controls:2.44%
cases:2.44%
controls:0.37%
—
—
cases:2.44%
controls:0.24%
cases:5.81%
controls:1.87%
cases:7.25%
controls:5.67%
10
81
236
2379
8
60
238
2400
6
9
240
2451
—
6
6
240
2451
14
45
227
2364
14
111
179
1848
General anesthesia, balanced
WX408 [2001310808]
1.3e-02
—
—
—
—
2.0e+00
1.4e+00
cases:3.25%
controls:3.21%
—
—
—
—
—
—
—
—
cases:5.81%
controls:0.79%
cases:12.95%
controls:3.47%
8
79
238
2381
—
—
—
—
14
19
227
2390
25
68
168
1891
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
1.4e-01
7.1e-01
2.3e+00
1.0e+50
1.8e+00
1.1e+00
2.9e-01
cases:7.32%
controls:6.42%
cases:6.10%
controls:3.09%
cases:4.07%
controls:0.41%
cases:2.85%
controls:0.00%
cases:2.44%
controls:0.41%
cases:8.71%
controls:3.11%
cases:10.36%
controls:7.96%
18
158
228
2302
15
76
231
2384
10
10
236
2450
7
0
239
2460
6
10
240
2447
21
75
220
2334
20
156
173
1803
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
4.0e-01
4.3e-01
1.8e+00
—
1.6e+00
5.9e-01
7.4e-02
cases:10.57%
controls:7.36%
cases:6.10%
controls:4.07%
cases:3.66%
controls:0.65%
—
—
cases:3.66%
controls:0.73%
cases:6.64%
controls:3.78%
cases:10.36%
controls:9.70%
26
181
220
2279
15
100
231
2360
9
16
237
2444
—
9
18
237
2439
16
91
225
2318
20
190
173
1769
Adenocarcinoma, NOS, of prostate gland
8140/3-C61.9 [44499685]
—
—
1.0e+50
1.0e+50
—
2.1e+00
1.2e+00
—
—
—
—
cases:6.91%
controls:0.00%
cases:3.66%
controls:0.00%
—
—
cases:5.81%
controls:0.75%
cases:7.77%
controls:2.40%
—
—
17
0
229
2460
9
0
237
2460
—
14
18
227
2391
15
47
178
1912
Uroflowmetry
44856007 [4261340]
3.0e-01
5.7e-01
—
1.0e+50
—
2.2e+00
1.1e+00
cases:6.50%
controls:4.92%
cases:2.85%
controls:1.63%
—
—
cases:9.76%
controls:0.00%
—
—
cases:10.37%
controls:1.25%
cases:16.58%
controls:6.33%
16
121
230
2339
7
40
239
2420
—
24
0
222
2460
—
25
30
216
2379
32
124
161
1835
Case Management Agency
251B00000X [38004193]
-7.2e-02
2.6e-01
3.4e-01
3.3e+00
4.4e-01
4.5e-01
2.6e-01
cases:51.63%
controls:53.41%
cases:53.66%
controls:47.07%
cases:24.80%
controls:19.02%
cases:23.58%
controls:1.14%
cases:28.86%
controls:20.76%
cases:66.39%
controls:55.83%
cases:85.49%
controls:81.93%
127
1314
119
1146
132
1158
114
1302
61
468
185
1992
58
28
188
2432
71
510
175
1947
160
1345
81
1064
165
1605
28
354
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
5.2e-01
1.0e+00
2.2e+00
—
1.5e+00
5.4e-01
4.0e-01
cases:13.01%
controls:8.13%
cases:10.98%
controls:4.35%
cases:4.07%
controls:0.45%
—
—
cases:2.44%
controls:0.57%
cases:7.47%
controls:4.48%
cases:16.06%
controls:11.33%
32
200
214
2260
27
107
219
2353
10
11
236
2449
—
6
14
240
2443
18
108
223
2301
31
222
162
1737
Pharmacy visit
OMOP4822462 [581458]
5.6e-01
5.5e-01
-4.1e-02
1.7e+00
2.0e-01
1.5e+00
9.8e-01
cases:97.15%
controls:95.12%
cases:93.50%
controls:89.23%
cases:52.44%
controls:53.46%
cases:11.38%
controls:2.28%
cases:59.76%
controls:54.86%
cases:97.51%
controls:89.66%
cases:98.96%
controls:97.29%
239
2340
7
120
230
2195
16
265
129
1315
117
1145
28
56
218
2404
147
1348
99
1109
235
2160
6
249
191
1906
2
53
General Surgery
2 [38004447]
7.2e-02
2.7e-01
7.4e-01
1.0e+50
2.3e+00
9.5e-01
4.7e-01
cases:25.61%
controls:24.27%
cases:10.16%
controls:7.93%
cases:2.44%
controls:1.18%
cases:20.33%
controls:0.00%
cases:12.20%
controls:1.42%
cases:17.84%
controls:7.76%
cases:26.94%
controls:18.68%
63
597
183
1863
25
195
221
2265
6
29
240
2431
50
0
196
2460
30
35
216
2422
43
187
198
2222
52
366
141
1593
Prostate cancer
116 [2001600116]
-1.0e+50
-1.0e+50
—
—
1.0e+50
3.2e+00
1.3e+00
cases:0.00%
controls:1.91%
cases:0.00%
controls:0.45%
—
—
—
—
cases:2.85%
controls:0.00%
cases:10.79%
controls:0.50%
cases:5.70%
controls:1.63%
0
47
246
2413
0
11
246
2449
—
—
7
0
239
2457
26
12
215
2397
11
32
182
1927
Transurethral resection of prostate
KED22 [2001306138]
—
-1.0e+50
—
—
—
3.0e+00
9.6e-01
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:4.98%
controls:0.25%
cases:4.66%
controls:1.84%
—
0
12
246
2448
—
—
—
12
6
229
2403
9
36
184
1923
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
1.5e-01
3.4e-01
2.9e+00
—
—
8.2e-01
-2.2e-01
cases:4.47%
controls:3.86%
cases:2.85%
controls:2.03%
cases:3.66%
controls:0.20%
—
—
—
—
cases:4.15%
controls:1.87%
cases:6.22%
controls:7.66%
11
95
235
2365
7
50
239
2410
9
5
237
2455
—
—
10
45
231
2364
12
150
181
1809
pH of Serum or Plasma
2753-2 [3018418]
2.5e-01
-4.0e-01
—
—
2.8e+00
7.4e-01
2.1e-01
cases:5.28%
controls:4.15%
cases:2.03%
controls:3.01%
—
—
—
—
cases:3.25%
controls:0.20%
cases:4.56%
controls:2.24%
cases:7.77%
controls:6.38%
13
102
233
2358
5
74
241
2386
—
—
8
5
238
2452
11
54
230
2355
15
125
178
1834
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
3.0e-01
8.2e-01
2.0e+00
—
1.2e+00
3.4e-01
-8.6e-03
cases:16.67%
controls:12.89%
cases:14.63%
controls:6.99%
cases:6.50%
controls:0.98%
—
—
cases:2.85%
controls:0.85%
cases:9.96%
controls:7.26%
cases:21.24%
controls:21.39%
41
317
205
2143
36
172
210
2288
16
24
230
2436
—
7
21
239
2436
24
175
217
2234
41
419
152
1540
Robot assisted procedure
ZXC96 [2001311382]
—
—
—
—
—
1.0e+50
2.7e+00
—
—
—
—
—
—
—
—
—
—
cases:9.54%
controls:0.00%
cases:5.18%
controls:0.36%
—
—
—
—
—
23
0
218
2409
10
7
183
1952
Percutaneous endoscopic radical prostatectomy
KEC01 [2001306131]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.18%
controls:0.36%
—
—
—
—
—
—
10
7
183
1952
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
1.7e-01
—
—
—
—
1.7e+00
1.0e+00
cases:3.25%
controls:2.76%
—
—
—
—
—
—
—
—
cases:4.56%
controls:0.87%
cases:8.81%
controls:3.37%
8
68
238
2392
—
—
—
—
11
21
230
2388
17
66
176
1893
dutasteride; oral
G04CB02 [21602676]
9.0e-01
9.5e-01
1.1e+00
—
1.8e+00
8.2e-01
8.6e-01
cases:7.72%
controls:3.29%
cases:5.69%
controls:2.28%
cases:2.44%
controls:0.81%
—
—
cases:2.85%
controls:0.49%
cases:5.39%
controls:2.45%
cases:10.36%
controls:4.65%
19
81
227
2379
14
56
232
2404
6
20
240
2440
—
7
12
239
2445
13
59
228
2350
20
91
173
1868
tamsulosin and dutasteride
G04CA52 [21602673]
5.5e-01
7.0e-01
1.3e+00
—
1.6e+00
1.1e+00
4.2e-01
cases:6.50%
controls:3.86%
cases:6.10%
controls:3.13%
cases:3.25%
controls:0.89%
—
—
cases:4.88%
controls:1.06%
cases:10.79%
controls:4.03%
cases:11.40%
controls:7.76%
16
95
230
2365
15
77
231
2383
8
22
238
2438
—
12
26
234
2431
26
97
215
2312
22
152
171
1807
Cystoscopy
UKC02 [2001306005]
1.7e-01
2.7e-01
—
1.0e+50
—
1.4e+00
1.2e+00
cases:4.88%
controls:4.15%
cases:2.44%
controls:1.87%
—
—
cases:2.03%
controls:0.00%
—
—
cases:7.05%
controls:1.78%
cases:14.51%
controls:5.00%
12
102
234
2358
6
46
240
2414
—
5
0
241
2460
—
17
43
224
2366
28
98
165
1861
pH of Urine
2756-5 [3015736]
3.9e-01
8.9e-01
2.6e+00
—
—
8.0e-01
8.0e-02
cases:7.72%
controls:5.37%
cases:6.91%
controls:2.97%
cases:4.07%
controls:0.33%
—
—
—
—
cases:7.47%
controls:3.49%
cases:11.40%
controls:10.62%
19
132
227
2328
17
73
229
2387
10
8
236
2452
—
—
18
84
223
2325
22
208
171
1751
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
-2.0e-01
8.2e-03
—
—
2.6e+00
2.6e-01
3.8e-01
cases:6.50%
controls:7.80%
cases:5.28%
controls:5.24%
—
—
—
—
cases:4.07%
controls:0.33%
cases:5.81%
controls:4.52%
cases:16.06%
controls:11.59%
16
192
230
2268
13
129
233
2331
—
—
10
8
236
2449
14
109
227
2300
31
227
162
1732
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
2.1e-01
2.3e-01
2.5e+00
—
—
3.8e-01
-1.8e-01
cases:6.50%
controls:5.33%
cases:3.66%
controls:2.93%
cases:4.47%
controls:0.37%
—
—
—
—
cases:4.56%
controls:3.15%
cases:8.81%
controls:10.36%
16
131
230
2329
9
72
237
2388
11
9
235
2451
—
—
11
76
230
2333
17
203
176
1756
Stress incontinence
N39.3 [45539046]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.11%
controls:0.26%
—
—
—
—
—
—
6
5
187
1954
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
7.2e-02
—
2.5e+00
—
—
-2.1e-02
-3.8e-01
cases:3.66%
controls:3.41%
—
—
cases:2.44%
controls:0.20%
—
—
—
—
cases:2.07%
controls:2.12%
cases:4.15%
controls:5.92%
9
84
237
2376
—
6
5
240
2455
—
—
5
51
236
2358
8
116
185
1843
Physiologic investigation of micturition
XKD06 [2001306098]
-1.0e+50
—
—
—
—
—
2.5e+00
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:3.63%
controls:0.31%
0
9
246
2451
—
—
—
—
—
7
6
186
1953
alprostadil; implant, parenteral
G04BE01 [21602646]
-1.0e+50
—
—
—
—
—
2.5e+00
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
cases:4.66%
controls:0.41%
0
16
246
2444
—
—
—
—
—
9
8
184
1951
Observation for other suspected diseases and conditions
Z03.8 [45585798]
1.7e+00
—
—
—
—
—
2.5e+00
cases:2.03%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:5.70%
controls:0.51%
5
9
241
2451
—
—
—
—
—
11
10
182
1949
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
2.0e-01
6.1e-01
2.4e+00
1.0e+50
—
6.4e-01
2.0e-01
cases:8.13%
controls:6.75%
cases:7.32%
controls:4.11%
cases:5.28%
controls:0.49%
cases:2.03%
controls:0.00%
—
—
cases:8.30%
controls:4.57%
cases:15.54%
controls:13.07%
20
166
226
2294
18
101
228
2359
13
12
233
2448
5
0
241
2460
—
20
110
221
2299
30
256
163
1703
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
1.3e-01
6.4e-01
2.4e+00
1.0e+50
—
7.1e-01
1.0e-01
cases:7.32%
controls:6.50%
cases:7.32%
controls:3.98%
cases:5.28%
controls:0.49%
cases:2.03%
controls:0.00%
—
—
cases:8.71%
controls:4.48%
cases:13.99%
controls:12.81%
18
160
228
2300
18
98
228
2362
13
12
233
2448
5
0
241
2460
—
21
108
220
2301
27
251
166
1708
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
1.7e-01
6.5e-01
2.4e+00
1.0e+50
—
6.9e-01
1.3e-01
cases:7.72%
controls:6.59%
cases:7.32%
controls:3.94%
cases:5.28%
controls:0.49%
cases:2.03%
controls:0.00%
—
—
cases:8.71%
controls:4.57%
cases:14.51%
controls:12.97%
19
162
227
2298
18
97
228
2363
13
12
233
2448
5
0
241
2460
—
21
110
220
2299
28
254
165
1705
Retention of urine
R33 [45587507]
-7.9e-02
8.3e-01
1.0e+50
1.0e+50
—
2.4e+00
6.6e-01
cases:2.03%
controls:2.20%
cases:2.03%
controls:0.89%
cases:2.03%
controls:0.00%
cases:4.07%
controls:0.00%
—
—
cases:7.05%
controls:0.66%
cases:5.18%
controls:2.76%
5
54
241
2406
5
22
241
2438
5
0
241
2460
10
0
236
2460
—
17
16
224
2393
10
54
183
1905
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
-1.4e-01
1.7e-01
—
—
2.3e+00
6.4e-01
5.5e-01
cases:6.50%
controls:7.40%
cases:5.28%
controls:4.51%
—
—
—
—
cases:3.25%
controls:0.33%
cases:6.64%
controls:3.61%
cases:15.54%
controls:9.60%
16
182
230
2278
13
111
233
2349
—
—
8
8
238
2449
16
87
225
2322
30
188
163
1771
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
1.3e-01
5.9e-01
1.6e+00
—
1.2e+00
1.8e-01
6.7e-01
cases:18.70%
controls:16.75%
cases:17.48%
controls:10.53%
cases:7.72%
controls:1.59%
—
—
cases:4.07%
controls:1.30%
cases:13.69%
controls:11.66%
cases:44.56%
controls:29.05%
46
412
200
2048
43
259
203
2201
19
39
227
2421
—
10
32
236
2425
33
281
208
2128
86
569
107
1390
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
8.4e-02
5.5e-01
1.6e+00
—
1.1e+00
7.0e-01
7.1e-01
cases:12.60%
controls:11.71%
cases:10.16%
controls:6.14%
cases:4.47%
controls:0.98%
—
—
cases:3.25%
controls:1.10%
cases:11.62%
controls:6.10%
cases:28.50%
controls:16.33%
31
288
215
2172
25
151
221
2309
11
24
235
2436
—
8
27
238
2430
28
147
213
2262
55
320
138
1639
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2.5e-01
1.3e-01
1.5e+00
—
2.2e+00
4.5e-01
3.8e-01
cases:12.60%
controls:10.12%
cases:4.47%
controls:3.94%
cases:2.44%
controls:0.57%
—
—
cases:4.07%
controls:0.45%
cases:7.47%
controls:4.90%
cases:18.65%
controls:13.53%
31
249
215
2211
11
97
235
2363
6
14
240
2446
—
10
11
236
2446
18
118
223
2291
36
265
157
1694
Abdominal CT examination
JN3AD [2001305554]
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.32%
controls:0.37%
—
—
—
—
—
—
—
8
9
233
2400
—
Thorax X-ray examination
GD1AA [2001303617]
2.8e-01
1.5e-01
—
1.0e+50
1.4e+00
1.6e+00
6.5e-01
cases:12.60%
controls:9.84%
cases:4.88%
controls:4.23%
—
—
cases:5.28%
controls:0.00%
cases:2.03%
controls:0.53%
cases:19.50%
controls:4.86%
cases:22.80%
controls:13.32%
31
242
215
2218
12
104
234
2356
—
13
0
233
2460
5
13
241
2444
47
117
194
2292
44
261
149
1698
Rectal ultrasound examination of prostate
KE1BE [2001306106]
1.1e-01
—
—
1.0e+50
—
2.2e+00
8.6e-01
cases:2.44%
controls:2.20%
—
—
—
—
cases:8.94%
controls:0.00%
—
—
cases:5.39%
controls:0.62%
cases:7.25%
controls:3.22%
6
54
240
2406
—
—
22
0
224
2460
—
13
15
228
2394
14
63
179
1896
Differential panel, method unspecified - Blood
69738-3 [42870588]
3.9e-01
-4.7e-01
—
—
2.2e+00
2.9e-01
6.4e-01
cases:6.91%
controls:4.80%
cases:2.03%
controls:3.21%
—
—
—
—
cases:2.85%
controls:0.33%
cases:4.56%
controls:3.45%
cases:10.88%
controls:6.07%
17
118
229
2342
5
79
241
2381
—
—
7
8
239
2449
11
83
230
2326
21
119
172
1840
norfloxacin; oral
J01MA06 [21603013]
1.3e+00
2.3e+00
—
—
—
2.2e+00
—
cases:2.85%
controls:0.77%
cases:2.03%
controls:0.20%
—
—
—
—
—
—
cases:2.49%
controls:0.29%
—
—
7
19
239
2441
5
5
241
2455
—
—
—
6
7
235
2402
—
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
8.1e-01
9.9e-01
—
—
—
1.3e+00
4.9e-01
cases:9.35%
controls:4.39%
cases:4.07%
controls:1.54%
—
—
—
—
—
—
cases:4.98%
controls:1.37%
cases:5.70%
controls:3.57%
23
108
223
2352
10
38
236
2422
—
—
—
12
33
229
2376
11
70
182
1889
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
4.9e-01
1.5e-01
1.7e+00
—
2.1e+00
3.3e-01
-4.5e-01
cases:6.10%
controls:3.82%
cases:2.44%
controls:2.11%
cases:2.03%
controls:0.37%
—
—
cases:2.85%
controls:0.37%
cases:3.32%
controls:2.41%
cases:4.66%
controls:7.10%
15
94
231
2366
6
52
240
2408
5
9
241
2451
—
7
9
239
2448
8
58
233
2351
9
139
184
1820
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.0e-01
1.9e-01
9.2e-01
—
1.1e+00
1.9e-01
2.3e-01
cases:25.61%
controls:23.74%
cases:23.17%
controls:19.92%
cases:10.16%
controls:4.31%
—
—
cases:11.79%
controls:4.19%
cases:25.31%
controls:21.83%
cases:49.74%
controls:44.05%
63
584
183
1876
57
490
189
1970
25
106
221
2354
—
29
103
217
2354
61
526
180
1883
96
863
97
1096
Basophils/Leukocytes in Blood
30180-4 [3022096]
2.5e-01
-5.2e-01
—
—
2.0e+00
1.7e-01
2.6e-01
cases:8.54%
controls:6.75%
cases:2.85%
controls:4.67%
—
—
—
—
cases:3.25%
controls:0.45%
cases:5.39%
controls:4.61%
cases:12.95%
controls:10.26%
21
166
225
2294
7
115
239
2345
—
—
8
11
238
2446
13
111
228
2298
25
201
168
1758
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.1e-01
1.9e-01
9.2e-01
—
1.1e+00
2.0e-01
2.3e-01
cases:25.61%
controls:23.54%
cases:22.76%
controls:19.63%
cases:9.76%
controls:4.15%
—
—
cases:11.38%
controls:4.15%
cases:25.31%
controls:21.79%
cases:49.22%
controls:43.54%
63
579
183
1881
56
483
190
1977
24
102
222
2358
—
28
102
218
2355
61
525
180
1884
95
853
98
1106
FEV1 percent change
69983-5 [42868472]
7.6e-01
1.8e+00
—
—
—
—
1.9e+00
cases:3.25%
controls:1.54%
cases:2.44%
controls:0.41%
—
—
—
—
—
—
—
—
cases:5.70%
controls:0.87%
8
38
238
2422
6
10
240
2450
—
—
—
—
11
17
182
1942
FVC percent change Respiratory system
69982-7 [42868471]
7.6e-01
1.8e+00
—
—
—
—
1.9e+00
cases:3.25%
controls:1.54%
cases:2.44%
controls:0.41%
—
—
—
—
—
—
—
—
cases:5.70%
controls:0.87%
8
38
238
2422
6
10
240
2450
—
—
—
—
11
17
182
1942
FEV1 --post bronchodilation
20155-8 [3023550]
7.6e-01
1.8e+00
—
—
—
—
1.9e+00
cases:3.25%
controls:1.54%
cases:2.44%
controls:0.41%
—
—
—
—
—
—
—
—
cases:5.70%
controls:0.87%
8
38
238
2422
6
10
240
2450
—
—
—
—
11
17
182
1942
FEV1/FVC --post bronchodilation
69970-2 [42868459]
7.6e-01
1.8e+00
—
—
—
—
1.9e+00
cases:3.25%
controls:1.54%
cases:2.44%
controls:0.41%
—
—
—
—
—
—
—
—
cases:5.70%
controls:0.87%
8
38
238
2422
6
10
240
2450
—
—
—
—
11
17
182
1942
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
7.6e-01
1.8e+00
—
—
—
—
1.9e+00
cases:3.25%
controls:1.54%
cases:2.44%
controls:0.41%
—
—
—
—
—
—
—
—
cases:5.70%
controls:0.87%
8
38
238
2422
6
10
240
2450
—
—
—
—
11
17
182
1942
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
2.5e-01
-5.2e-01
—
—
1.9e+00
1.6e-01
2.8e-01
cases:8.54%
controls:6.79%
cases:2.85%
controls:4.67%
—
—
—
—
cases:3.25%
controls:0.49%
cases:5.39%
controls:4.65%
cases:12.95%
controls:10.11%
21
167
225
2293
7
115
239
2345
—
—
8
12
238
2445
13
112
228
2297
25
198
168
1761
Monocytes/Leukocytes in Blood
26485-3 [3019069]
2.9e-01
-5.2e-01
—
—
1.9e+00
1.6e-01
3.3e-01
cases:8.94%
controls:6.87%
cases:2.85%
controls:4.67%
—
—
—
—
cases:3.25%
controls:0.49%
cases:5.39%
controls:4.65%
cases:13.47%
controls:10.06%
22
169
224
2291
7
115
239
2345
—
—
8
12
238
2445
13
112
228
2297
26
197
167
1762
Abdominal CT examination both without and with contrast
JN3CD [2001305561]
—
—
—
1.0e+50
—
—
1.9e+00
—
—
—
—
—
—
cases:2.85%
controls:0.00%
—
—
—
—
cases:4.66%
controls:0.71%
—
—
—
7
0
239
2460
—
—
9
14
184
1945
Emergency Medicine
93 [38004510]
2.1e-01
5.9e-01
1.1e+00
—
—
1.2e+00
7.2e-01
cases:11.79%
controls:9.76%
cases:9.76%
controls:5.65%
cases:2.85%
controls:0.93%
—
—
—
—
cases:18.26%
controls:6.52%
cases:30.05%
controls:17.30%
29
240
217
2220
24
139
222
2321
7
23
239
2437
—
—
44
157
197
2252
58
339
135
1620
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
7.3e-02
1.8e-01
8.3e-01
—
1.0e+00
1.7e-01
1.7e-01
cases:26.02%
controls:24.63%
cases:24.80%
controls:21.67%
cases:11.38%
controls:5.28%
—
—
cases:13.01%
controls:5.01%
cases:26.97%
controls:23.83%
cases:50.78%
controls:46.55%
64
606
182
1854
61
533
185
1927
28
130
218
2330
—
32
123
214
2334
65
574
176
1835
98
912
95
1047
Acute tubulo-interstitial nephritis
N10 [45543856]
—
—
—
—
—
1.9e+00
-1.0e-01
—
—
—
—
—
—
—
—
—
—
cases:2.90%
controls:0.46%
cases:2.59%
controls:2.86%
—
—
—
—
—
7
11
234
2398
5
56
188
1903
Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:19.69%
controls:3.73%
—
—
—
—
—
—
38
73
155
1886
Eosinophils [#/volume] in Blood
26449-9 [3013115]
2.3e-01
-4.0e-01
—
—
1.8e+00
2.4e-01
1.7e-01
cases:8.94%
controls:7.24%
cases:3.25%
controls:4.80%
—
—
—
—
cases:3.25%
controls:0.53%
cases:5.81%
controls:4.61%
cases:13.47%
controls:11.59%
22
178
224
2282
8
118
238
2342
—
—
8
13
238
2444
14
111
227
2298
26
227
167
1732
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
2.5e-01
-6.9e-01
—
—
1.8e+00
1.0e-01
7.4e-02
cases:8.94%
controls:7.07%
cases:2.44%
controls:4.76%
—
—
—
—
cases:3.25%
controls:0.53%
cases:5.39%
controls:4.90%
cases:11.40%
controls:10.67%
22
174
224
2286
6
117
240
2343
—
—
8
13
238
2444
13
118
228
2291
22
209
171
1750
Basophils [#/volume] in Blood
26444-0 [3006315]
2.2e-01
-6.9e-01
—
—
1.8e+00
2.6e-01
2.2e-02
cases:8.54%
controls:6.99%
cases:2.44%
controls:4.76%
—
—
—
—
cases:3.25%
controls:0.53%
cases:5.81%
controls:4.52%
cases:11.40%
controls:11.18%
21
172
225
2288
6
117
240
2343
—
—
8
13
238
2444
14
109
227
2300
22
219
171
1740
Monocytes [#/volume] in Blood
26484-6 [3001604]
2.7e-01
-6.9e-01
—
—
1.8e+00
2.5e-01
2.7e-02
cases:8.94%
controls:6.95%
cases:2.44%
controls:4.76%
—
—
—
—
cases:3.25%
controls:0.53%
cases:5.81%
controls:4.57%
cases:11.40%
controls:11.13%
22
171
224
2289
6
117
240
2343
—
—
8
13
238
2444
14
110
227
2299
22
218
171
1741
pH of Specimen
17433-4 [3019225]
—
—
—
—
—
-1.0e+50
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
cases:8.81%
controls:1.53%
—
—
—
—
—
0
18
241
2391
17
30
176
1929
Simple examination of mouth
SAA01 [2001310274]
-3.5e-02
3.4e-01
1.8e+00
—
7.0e-01
2.3e-01
1.5e-01
cases:13.41%
controls:13.82%
cases:10.16%
controls:7.48%
cases:2.85%
controls:0.49%
—
—
cases:2.03%
controls:1.02%
cases:9.96%
controls:8.09%
cases:26.42%
controls:23.53%
33
340
213
2120
25
184
221
2276
7
12
239
2448
—
5
25
241
2432
24
195
217
2214
51
461
142
1498
Gas panel - Venous blood
24339-4 [3000991]
—
1.8e+00
—
—
—
—
—
—
—
cases:2.85%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
7
12
239
2448
—
—
—
—
—
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
2.6e-01
-7.2e-01
—
—
1.8e+00
2.1e-01
-1.1e-01
cases:9.35%
controls:7.36%
cases:2.44%
controls:4.88%
—
—
—
—
cases:3.25%
controls:0.57%
cases:5.81%
controls:4.77%
cases:10.88%
controls:12.05%
23
181
223
2279
6
120
240
2340
—
—
8
14
238
2443
14
115
227
2294
21
236
172
1723
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
6.1e-01
1.7e+00
—
—
—
—
1.7e+00
cases:2.44%
controls:1.34%
cases:2.03%
controls:0.37%
—
—
—
—
—
—
—
—
cases:9.84%
controls:1.94%
6
33
240
2427
5
9
241
2451
—
—
—
—
19
38
174
1921
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
1.0e-01
2.6e-01
8.4e-01
—
1.1e+00
3.2e-01
5.8e-01
cases:19.51%
controls:17.93%
cases:19.11%
controls:15.37%
cases:8.54%
controls:3.86%
—
—
cases:9.76%
controls:3.42%
cases:21.99%
controls:16.98%
cases:40.41%
controls:27.57%
48
441
198
2019
47
378
199
2082
21
95
225
2365
—
24
84
222
2373
53
409
188
2000
78
540
115
1419
enoxaparin; parenteral
B01AB05 [21600976]
1.3e-01
1.3e-01
—
—
—
1.7e+00
4.0e-01
cases:6.50%
controls:5.73%
cases:2.03%
controls:1.79%
—
—
—
—
—
—
cases:8.30%
controls:1.66%
cases:9.33%
controls:6.43%
16
141
230
2319
5
44
241
2416
—
—
—
20
40
221
2369
18
126
175
1833
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
1.2e-01
-1.0e-02
9.3e-01
—
1.6e+00
7.2e-01
-4.1e-02
cases:8.13%
controls:7.28%
cases:4.07%
controls:4.11%
cases:2.44%
controls:0.98%
—
—
cases:4.07%
controls:0.81%
cases:9.54%
controls:4.90%
cases:11.92%
controls:12.35%
20
179
226
2281
10
101
236
2359
6
24
240
2436
—
10
20
236
2437
23
118
218
2291
23
242
170
1717
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
-2.7e-01
—
—
—
—
—
1.6e+00
cases:2.03%
controls:2.64%
—
—
—
—
—
—
—
—
—
—
cases:17.62%
controls:4.34%
5
65
241
2395
—
—
—
—
—
34
85
159
1874
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
4.5e-01
—
—
—
—
—
1.5e+00
cases:2.03%
controls:1.30%
—
—
—
—
—
—
—
—
—
—
cases:5.18%
controls:1.23%
5
32
241
2428
—
—
—
—
—
10
24
183
1935
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
-1.0e-01
-3.4e-02
1.0e+00
—
1.4e+00
4.6e-01
7.5e-02
cases:13.01%
controls:14.19%
cases:7.72%
controls:7.97%
cases:4.88%
controls:1.79%
—
—
cases:5.28%
controls:1.34%
cases:13.28%
controls:8.84%
cases:23.32%
controls:22.00%
32
349
214
2111
19
196
227
2264
12
44
234
2416
—
13
33
233
2424
32
213
209
2196
45
431
148
1528
naproxcinod
M01AE18 [40254094]
5.5e-01
-4.0e-02
—
—
—
1.4e+00
2.2e-01
cases:10.98%
controls:6.67%
cases:2.03%
controls:2.11%
—
—
—
—
—
—
cases:6.22%
controls:1.62%
cases:6.22%
controls:5.05%
27
164
219
2296
5
52
241
2408
—
—
—
15
39
226
2370
12
99
181
1860
naproxen; oral, rectal
M01AE02 [21603968]
5.5e-01
-4.0e-02
—
—
—
1.4e+00
2.2e-01
cases:10.98%
controls:6.67%
cases:2.03%
controls:2.11%
—
—
—
—
—
—
cases:6.22%
controls:1.62%
cases:6.22%
controls:5.05%
27
164
219
2296
5
52
241
2408
—
—
—
15
39
226
2370
12
99
181
1860
Outpatient Hospital
22 [8756]
-1.6e-01
8.3e-02
5.9e-01
—
1.3e+00
1.4e+00
5.2e-01
cases:26.42%
controls:29.72%
cases:10.16%
controls:9.43%
cases:2.03%
controls:1.14%
—
—
cases:4.07%
controls:1.18%
cases:28.22%
controls:8.97%
cases:39.90%
controls:28.38%
65
731
181
1729
25
232
221
2228
5
28
241
2432
—
10
29
236
2428
68
216
173
2193
77
556
116
1403
Extensive abdominal CT
JN3BD [2001305556]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.22%
controls:1.63%
—
—
—
—
—
—
12
32
181
1927
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
3.3e-02
3.0e-01
—
1.0e+50
—
1.4e+00
4.0e-01
cases:8.13%
controls:7.89%
cases:3.66%
controls:2.72%
—
—
cases:2.03%
controls:0.00%
—
—
cases:8.30%
controls:2.28%
cases:12.95%
controls:9.09%
20
194
226
2266
9
67
237
2393
—
5
0
241
2460
—
20
55
221
2354
25
178
168
1781
Other specified counselling
Z71.8 [45581061]
3.5e-01
6.8e-01
—
—
-1.0e+50
1.4e+00
6.0e-01
cases:3.25%
controls:2.32%
cases:2.85%
controls:1.46%
—
—
—
—
cases:0.00%
controls:0.28%
cases:5.39%
controls:1.45%
cases:6.74%
controls:3.83%
8
57
238
2403
7
36
239
2424
—
—
0
7
246
2450
13
35
228
2374
13
75
180
1884
Removal of sutures
SPAT1153 [2001700254]
-4.2e-01
—
—
—
—
1.3e+00
6.1e-01
cases:3.25%
controls:4.88%
—
—
—
—
—
—
—
—
cases:4.56%
controls:1.25%
cases:12.95%
controls:7.45%
8
120
238
2340
—
—
—
—
11
30
230
2379
25
146
168
1813
Issue of repeat prescription
Z76.0 [45542456]
8.7e-01
1.6e+00
—
—
—
1.3e+00
8.4e-01
cases:3.25%
controls:1.38%
cases:3.25%
controls:0.69%
—
—
—
—
—
—
cases:4.98%
controls:1.45%
cases:6.74%
controls:3.01%
8
34
238
2426
8
17
238
2443
—
—
—
12
35
229
2374
13
59
180
1900
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
7.0e-02
5.9e-01
—
—
—
1.3e+00
5.8e-01
cases:8.54%
controls:8.01%
cases:4.47%
controls:2.52%
—
—
—
—
—
—
cases:9.54%
controls:2.91%
cases:11.92%
controls:7.04%
21
197
225
2263
11
62
235
2398
—
—
—
23
70
218
2339
23
138
170
1821
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.3e-01
4.0e-01
9.3e-01
—
1.2e+00
4.2e-01
2.7e-01
cases:23.98%
controls:20.08%
cases:18.70%
controls:13.37%
cases:6.91%
controls:2.85%
—
—
cases:9.76%
controls:3.01%
cases:20.75%
controls:14.69%
cases:39.38%
controls:33.13%
59
494
187
1966
46
329
200
2131
17
70
229
2390
—
24
74
222
2383
50
354
191
2055
76
649
117
1310
Inpatient Hospital
21 [8717]
-2.2e-01
-3.3e-03
7.5e-01
—
7.7e-01
1.2e+00
4.3e-01
cases:32.93%
controls:37.85%
cases:14.63%
controls:14.67%
cases:4.47%
controls:2.15%
—
—
cases:5.69%
controls:2.73%
cases:34.85%
controls:14.20%
cases:47.15%
controls:36.65%
81
931
165
1529
36
361
210
2099
11
53
235
2407
—
14
67
232
2390
84
342
157
2067
91
718
102
1241
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
0.0e+00
—
—
—
—
—
1.2e+00
cases:2.03%
controls:2.03%
—
—
—
—
—
—
—
—
—
—
cases:7.25%
controls:2.40%
5
50
241
2410
—
—
—
—
—
14
47
179
1912
Pure hypercholesterolaemia
E78.01 [2000501514]
3.0e-01
1.4e-01
-1.0e+50
1.0e+50
1.8e+00
1.0e+00
6.1e-01
cases:5.28%
controls:3.98%
cases:2.85%
controls:2.48%
cases:0.00%
controls:0.33%
cases:5.69%
controls:0.00%
cases:2.03%
controls:0.33%
cases:7.05%
controls:2.66%
cases:11.40%
controls:6.53%
13
98
233
2362
7
61
239
2399
0
8
246
2452
14
0
232
2460
5
8
241
2449
17
64
224
2345
22
128
171
1831
erdosteine; oral
R05CB15 [21603394]
7.1e-01
—
—
—
—
—
1.0e+00
cases:3.66%
controls:1.83%
—
—
—
—
—
—
—
—
—
—
cases:9.84%
controls:3.83%
9
45
237
2415
—
—
—
—
—
19
75
174
1884
alfuzosin; oral
G04CA01 [21602668]
4.2e-01
6.2e-01
—
—
—
1.0e+00
5.4e-01
cases:8.13%
controls:5.49%
cases:5.69%
controls:3.13%
—
—
—
—
—
—
cases:7.47%
controls:2.86%
cases:8.81%
controls:5.31%
20
135
226
2325
14
77
232
2383
—
—
—
18
69
223
2340
17
104
176
1855
Person consulting for explanation of investigation findings
Z71.2 [45552100]
9.8e-01
8.8e-01
—
—
—
1.1e+00
2.5e-01
cases:8.13%
controls:3.21%
cases:3.66%
controls:1.54%
—
—
—
—
—
—
cases:4.98%
controls:1.74%
cases:6.22%
controls:4.90%
20
79
226
2381
9
38
237
2422
—
—
—
12
42
229
2367
12
96
181
1863
sildenafil; oral
G04BE03 [21602648]
-8.4e-02
-2.2e-01
—
—
—
5.1e-01
9.6e-01
cases:4.88%
controls:5.28%
cases:2.85%
controls:3.54%
—
—
—
—
—
—
cases:5.81%
controls:3.57%
cases:20.73%
controls:9.14%
12
130
234
2330
7
87
239
2373
—
—
—
14
86
227
2323
40
179
153
1780
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1.3e-01
-9.6e-02
7.8e-01
—
9.5e-01
1.3e-01
2.0e-01
cases:25.61%
controls:23.25%
cases:16.67%
controls:18.05%
cases:7.32%
controls:3.50%
—
—
cases:7.32%
controls:2.97%
cases:20.75%
controls:18.68%
cases:46.63%
controls:41.60%
63
572
183
1888
41
444
205
2016
18
86
228
2374
—
18
73
228
2384
50
450
191
1959
90
815
103
1144
EKG study
11524-6 [3013512]
3.6e-02
-1.1e-01
—
—
—
3.7e-01
9.4e-01
cases:6.10%
controls:5.89%
cases:2.85%
controls:3.17%
—
—
—
—
—
—
cases:4.98%
controls:3.49%
cases:21.76%
controls:9.80%
15
145
231
2315
7
78
239
2382
—
—
—
12
84
229
2325
42
192
151
1767
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
—
—
—
—
—
3.5e-01
7.2e-01
—
—
—
—
—
—
—
—
—
—
cases:5.81%
controls:4.15%
cases:22.80%
controls:12.56%
—
—
—
—
—
14
100
227
2309
44
246
149
1713
tamsulosin; oral
G04CA02 [21602669]
3.6e-01
6.7e-01
6.5e-01
—
9.2e-01
5.7e-01
1.7e-01
cases:19.51%
controls:14.51%
cases:17.07%
controls:9.51%
cases:4.07%
controls:2.15%
—
—
cases:6.50%
controls:2.69%
cases:16.18%
controls:9.84%
cases:20.21%
controls:17.66%
48
357
198
2103
42
234
204
2226
10
53
236
2407
—
16
66
230
2391
39
237
202
2172
39
346
154
1613
pantoprazole; oral, parenteral
A02BC02 [21600097]
4.0e-01
3.1e-01
8.4e-01
—
7.3e-01
4.3e-01
6.0e-01
cases:22.36%
controls:16.14%
cases:12.60%
controls:9.55%
cases:5.28%
controls:2.36%
—
—
cases:4.07%
controls:1.99%
cases:16.60%
controls:11.46%
cases:33.16%
controls:21.34%
55
397
191
2063
31
235
215
2225
13
58
233
2402
—
10
49
236
2408
40
276
201
2133
64
418
129
1541
Emergency Room Visit
ER [9203]
-1.2e-01
8.9e-02
3.4e-01
—
1.1e+00
5.9e-01
3.2e-01
cases:33.74%
controls:36.46%
cases:15.04%
controls:13.94%
cases:2.85%
controls:2.03%
—
—
cases:5.28%
controls:1.87%
cases:24.07%
controls:14.99%
cases:47.15%
controls:39.41%
83
897
163
1563
37
343
209
2117
7
50
239
2410
—
13
46
233
2411
58
361
183
2048
91
772
102
1187
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
-3.7e-02
4.8e-02
7.6e-02
—
4.0e-01
5.7e-01
3.5e-01
cases:29.67%
controls:30.45%
cases:19.11%
controls:18.37%
cases:4.07%
controls:3.78%
—
—
cases:5.28%
controls:3.62%
cases:31.54%
controls:20.67%
cases:51.81%
controls:43.03%
73
749
173
1711
47
452
199
2008
10
93
236
2367
—
13
89
233
2368
76
498
165
1911
100
843
93
1116
carvedilol; oral
C07AG02 [21601700]
2.1e-02
—
—
—
—
—
9.2e-01
cases:2.03%
controls:1.99%
—
—
—
—
—
—
—
—
—
—
cases:3.63%
controls:1.48%
5
49
241
2411
—
—
—
—
—
7
29
186
1930
No disease
A97 [2002000230]
-1.0e+50
—
—
—
—
—
7.9e-01
cases:0.00%
controls:2.15%
—
—
—
—
—
—
—
—
—
—
cases:7.25%
controls:3.42%
0
53
246
2407
—
—
—
—
—
14
67
179
1892
General symptom/complaint other
A29 [2002000163]
—
—
—
—
—
—
-1.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.59%
controls:3.01%
—
—
—
—
—
—
5
59
188
1900
Teaching
WZC30 [2001310891]
2.8e-01
-1.0e+50
—
—
—
—
3.0e-01
cases:2.03%
controls:1.54%
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
cases:2.59%
controls:1.94%
5
38
241
2422
0
14
246
2446
—
—
—
—
5
38
188
1921
Lumbar spine X-ray examination with flexion
NA3EA [2001307044]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
9
193
1950
Beta 2 glycoprotein 1 IgG Ab [Units/volume] in Serum or Plasma by Immunoassay
44448-9 [3044355]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
—
—
fluticasone; inhalant
R03BA05 [21603288]
1.1e-01
3.6e-01
-1.0e+50
—
—
—
—
cases:2.85%
controls:2.56%
cases:2.03%
controls:1.42%
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
7
63
239
2397
5
35
241
2425
0
10
246
2450
—
—
—
—
Other medical or dental certificate
WZA90 [2001310883]
3.4e-01
—
—
—
—
—
7.3e-01
cases:2.85%
controls:2.03%
—
—
—
—
—
—
—
—
—
—
cases:6.74%
controls:3.37%
7
50
239
2410
—
—
—
—
—
13
66
180
1893
Other oral or dental procedure
SXC05 [2001310586]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
246
2454
—
—
—
—
—
—
Essential hypertension, Unspecified
4019X [2000403546]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
—
—
ropinirole; oral
N04BC04 [21604476]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.20%
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
0
8
246
2452
0
5
246
2455
—
—
—
0
5
241
2404
—
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
YJ2VG [2001305588]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
246
2452
—
—
—
—
—
—
Palmar fasciotomy of hand
NDM10 [2001307724]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
246
2448
—
—
—
—
—
—
Knee symptom/complaint
L15 [2002000639]
—
-1.0e+50
—
—
—
-1.0e+50
5.4e-01
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
cases:0.00%
controls:0.75%
cases:6.22%
controls:3.73%
—
0
19
246
2441
—
—
—
0
18
241
2391
12
73
181
1886
pseudoephedrine, combinations; oral
R01BA52 [21603213]
6.7e-02
—
—
—
—
1.0e+00
-1.2e-01
cases:3.25%
controls:3.05%
—
—
—
—
—
—
—
—
cases:2.49%
controls:0.91%
cases:3.63%
controls:4.08%
8
75
238
2385
—
—
—
—
6
22
235
2387
7
80
186
1879
Other polyp of sinus
J33.8 [45591556]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
246
2454
—
—
—
—
—
—
Ambulatory ECG
XF404 [2001303370]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
0
6
246
2454
—
—
—
—
0
26
193
1933
Fat metabolism disorder associated with chronic coronary artery disease
213 [2001600209]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.92%
—
—
—
—
—
0
6
241
2403
0
18
193
1941
Other specified intervertebral disc degeneration
M51.3 [45591865]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.82%
—
—
—
—
—
0
5
241
2404
0
16
193
1943
Other transduodenal endoscopic operation on bile duct or ampulla of Vater
JKE98 [2001305336]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
7
193
1952
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
351 [2001600312]
3.5e-02
-1.0e+50
—
—
—
—
3.0e-01
cases:2.44%
controls:2.36%
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
cases:3.63%
controls:2.71%
6
58
240
2402
0
10
246
2450
—
—
—
—
7
53
186
1906
misoprostol; oral, vaginal
G02AD06 [21602443]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
0
5
241
2404
—
Voluntary or Charitable Agency
251V00000X [38004202]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.63%
controls:0.71%
—
—
—
—
—
—
7
14
186
1945
Contusion of thigh
S70.1 [45608084]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
193
1954
Infective dermatitis
L30.3 [45577034]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
246
2450
—
—
—
—
—
—
Internal Medicine
11 [38004456]
7.5e-02
1.4e-01
1.8e-01
—
4.2e-01
1.9e-01
9.7e-02
cases:32.52%
controls:30.89%
cases:14.63%
controls:12.97%
cases:2.03%
controls:1.71%
—
—
cases:3.25%
controls:2.16%
cases:14.94%
controls:12.66%
cases:31.09%
controls:29.05%
80
760
166
1700
36
319
210
2141
5
42
241
2418
—
8
53
238
2404
36
305
205
2104
60
569
133
1390
beclometasone; nasal
R01AD01 [21605043]
6.6e-01
—
—
—
—
1.6e+00
—
cases:2.03%
controls:1.06%
—
—
—
—
—
—
—
—
cases:2.07%
controls:0.42%
—
—
5
26
241
2434
—
—
—
—
5
10
236
2399
—
General and Unspecified, Local injection/infiltration
A55 [2002000189]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
193
1954
Monitored bed care
WX892 [2001310850]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
0
8
246
2452
—
—
—
0
11
241
2398
—
Upper gastrointestinal surgery
106 [44777669]
1.1e-01
3.9e-01
8.9e-01
—
—
5.7e-01
2.5e-01
cases:11.38%
controls:10.33%
cases:5.69%
controls:3.94%
cases:2.44%
controls:1.02%
—
—
—
—
cases:7.88%
controls:4.61%
cases:16.06%
controls:13.02%
28
254
218
2206
14
97
232
2363
6
25
240
2435
—
—
19
111
222
2298
31
255
162
1704
Seropositive rheumatoid arthritis, unspecified
M05.9 [45553050]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
246
2454
—
—
—
—
—
—
Atherosclerosis of arteries of extremities
I70.2 [45538421]
-7.1e-02
—
—
—
—
—
1.4e-01
cases:2.85%
controls:3.05%
—
—
—
—
—
—
—
—
—
—
cases:4.66%
controls:4.08%
7
75
239
2385
—
—
—
—
—
9
80
184
1879
celecoxib; oral
M01AH01 [21603992]
2.0e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:2.03%
controls:1.67%
cases:0.00%
controls:0.41%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
5
41
241
2419
0
10
246
2450
—
—
—
0
7
241
2402
—
Apixaban, dabigatran, edoxaban and rivaroxaban for the long-term prevention of recurrent deep veinthrombosis and pulmonary embolism
379 [2001600340]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
—
—
Screening procedure
SPAT1324 [2001700425]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
193
1953
diclofenac, combinations; oral
M01AB55 [21603959]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
0
5
241
2404
—
Elastase.pancreatic [Mass/mass] in Stool
25907-7 [3000570]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
246
2454
—
—
—
—
—
—
Other specified urinary incontinence
N39.4 [45577525]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
0
11
246
2449
0
7
246
2453
—
—
—
—
—
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
1.8e-01
1.9e-01
—
—
—
4.2e-01
6.2e-03
cases:4.07%
controls:3.41%
cases:2.44%
controls:2.03%
—
—
—
—
—
—
cases:3.73%
controls:2.49%
cases:5.70%
controls:5.67%
10
84
236
2376
6
50
240
2410
—
—
—
9
60
232
2349
11
111
182
1848
rosuvastatin; oral
C10AA07 [21601862]
1.8e-01
1.1e-01
2.7e-01
—
3.4e-01
7.0e-02
2.1e-01
cases:8.54%
controls:7.24%
cases:6.91%
controls:6.22%
cases:2.85%
controls:2.20%
—
—
cases:2.44%
controls:1.75%
cases:7.88%
controls:7.39%
cases:11.92%
controls:9.90%
21
178
225
2282
17
153
229
2307
7
54
239
2406
—
6
43
240
2414
19
178
222
2231
23
194
170
1765
Counselling and guidance related to nutrition and weight management
SPAT1306 [2001700407]
-1.0e+50
—
-1.0e+50
—
—
—
5.3e-01
cases:0.00%
controls:1.26%
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:4.66%
controls:2.81%
0
31
246
2429
—
0
9
246
2451
—
—
—
9
55
184
1904
Catheterisation of left atrium or ventricle
TFC10 [2001303397]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
246
2451
—
—
—
—
—
—
cloxacillin; oral, parenteral
J01CF02 [21602854]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
246
2454
—
—
—
—
—
—
mometasone, combinations
R01AD59 [947911]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
193
1954
General Practice
1 [38004446]
-7.6e-02
9.0e-02
3.1e-01
1.0e+50
8.8e-01
5.0e-01
1.6e-01
cases:13.82%
controls:14.76%
cases:8.13%
controls:7.48%
cases:2.03%
controls:1.50%
cases:5.69%
controls:0.00%
cases:3.66%
controls:1.55%
cases:14.52%
controls:9.38%
cases:25.91%
controls:23.02%
34
363
212
2097
20
184
226
2276
5
37
241
2423
14
0
232
2460
9
38
237
2419
35
226
206
2183
50
451
143
1508
Presence of orthopaedic joint implants
Z96.6 [45600385]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
246
2452
—
—
—
—
—
—
Orthopedic Surgery
20 [38004465]
1.7e-01
2.1e-01
1.2e+00
—
—
-1.2e-01
2.6e-02
cases:17.07%
controls:14.84%
cases:6.50%
controls:5.33%
cases:2.03%
controls:0.65%
—
—
—
—
cases:5.39%
controls:6.06%
cases:15.54%
controls:15.21%
42
365
204
2095
16
131
230
2329
5
16
241
2444
—
—
13
146
228
2263
30
298
163
1661
hydrocortisone; local oral
A01AC03 [21600036]
5.5e-01
—
—
—
—
—
—
cases:2.85%
controls:1.67%
—
—
—
—
—
—
—
—
—
—
—
—
7
41
239
2419
—
—
—
—
—
—
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
1.5e-01
1.1e-01
3.9e-01
—
4.5e-01
-2.6e-01
1.5e-01
cases:22.76%
controls:20.28%
cases:14.63%
controls:13.33%
cases:2.44%
controls:1.67%
—
—
cases:2.03%
controls:1.30%
cases:10.79%
controls:13.57%
cases:39.90%
controls:36.35%
56
499
190
1961
36
328
210
2132
6
41
240
2419
—
5
32
241
2425
26
327
215
2082
77
712
116
1247
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
2.1e-01
2.9e-01
—
—
—
-3.4e-01
1.4e-01
cases:13.41%
controls:11.18%
cases:6.91%
controls:5.28%
—
—
—
—
—
—
cases:3.73%
controls:5.19%
cases:19.69%
controls:17.56%
33
275
213
2185
17
130
229
2330
—
—
—
9
125
232
2284
38
344
155
1615
Exposure to unspecified factor
X59 [45756412]
2.7e-01
—
—
—
—
-1.0e+50
4.5e-01
cases:2.44%
controls:1.87%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
cases:3.63%
controls:2.35%
6
46
240
2414
—
—
—
—
0
16
241
2393
7
46
186
1913
Post-traumatic arthrosis of other joints
M19.1 [45596496]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
8
193
1951
Benign neoplasm: Caecum
D12.0 [45586086]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
193
1953
Protein C actual/normal in Platelet poor plasma by Coagulation assay
27819-2 [3020287]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
246
2454
—
—
—
—
—
—
Haemorrhoids
K96 [2002000623]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
246
2454
—
—
—
—
—
—
Suture or treatment of traumatic wound
SPAT1149 [2001700250]
—
—
—
—
—
-1.0e+50
2.5e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:3.63%
controls:2.86%
—
—
—
—
—
0
11
241
2398
7
56
186
1903
Home Visit
OMOP4822459 [581476]
-6.1e-01
6.9e-02
—
—
8.6e-01
1.5e-01
4.1e-02
cases:2.85%
controls:5.12%
cases:4.47%
controls:4.19%
—
—
—
—
cases:2.85%
controls:1.22%
cases:5.81%
controls:5.02%
cases:12.44%
controls:12.00%
7
126
239
2334
11
103
235
2357
—
—
7
30
239
2427
14
121
227
2288
24
235
169
1724
Epilepsy
G40 [45595935]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
0
9
246
2451
—
—
—
—
—
0
11
193
1948
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
-9.5e-03
7.1e-01
—
—
—
—
7.5e-02
cases:4.47%
controls:4.51%
cases:3.25%
controls:1.63%
—
—
—
—
—
—
—
—
cases:5.70%
controls:5.31%
11
111
235
2349
8
40
238
2420
—
—
—
—
11
104
182
1855
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
1.7e-01
5.6e-02
1.7e-01
—
2.5e-01
-3.9e-01
2.5e-01
cases:21.54%
controls:18.74%
cases:13.82%
controls:13.17%
cases:2.44%
controls:2.07%
—
—
cases:2.03%
controls:1.59%
cases:9.96%
controls:13.99%
cases:39.38%
controls:33.64%
53
461
193
1999
34
324
212
2136
6
51
240
2409
—
5
39
241
2418
24
337
217
2072
76
659
117
1300
terbinafine; ointment
D01AE15 [21601954]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
11
241
2398
—
diclofenac
D11AX18 [21602355]
—
-1.0e+50
—
—
—
—
4.3e-01
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
cases:3.63%
controls:2.40%
—
0
9
246
2451
—
—
—
—
7
47
186
1912
Constipation
K59.0 [45557663]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
246
2445
—
—
—
—
—
—
Acute myocardial infarction, unspecified
I21.9 [45605780]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
193
1954
Stroke/cerebrovascular accident
K90 [2002000617]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
0
15
246
2445
0
9
246
2451
—
—
—
—
—
epitizide and potassium-sparing agents
C03EA03 [21601545]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
—
Extensive CT examination of pelvis for dose design of radiotherapy
YL1BD [2001305594]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
0
6
246
2454
—
—
—
—
—
0
7
193
1952
Unilateral or unspecified inguinal hernia, without obstruction or gangrene
K40.9 [45543307]
3.5e-01
—
-1.0e+50
—
—
—
1.8e-01
cases:4.88%
controls:3.50%
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
cases:4.66%
controls:3.93%
12
86
234
2374
—
0
5
246
2455
—
—
—
9
77
184
1882
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
4.9e-01
—
—
—
—
—
4.9e-01
cases:2.44%
controls:1.50%
—
—
—
—
—
—
—
—
—
—
cases:3.63%
controls:2.25%
6
37
240
2423
—
—
—
—
—
7
44
186
1915
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
-1.0e-01
3.3e-01
—
—
1.0e+00
1.8e-01
-7.9e-02
cases:9.76%
controls:10.69%
cases:6.91%
controls:5.08%
—
—
—
—
cases:2.03%
controls:0.73%
cases:6.22%
controls:5.23%
cases:14.51%
controls:15.52%
24
263
222
2197
17
125
229
2335
—
—
5
18
241
2439
15
126
226
2283
28
304
165
1655
Implantation of transvenous cardiac pacemaker with atrial and ventricular electrodes
FPE20 [2001303170]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
10
193
1949
Emergency treatment
SGA01 [2001310379]
—
1.6e+00
—
—
—
—
3.0e-01
—
—
cases:2.03%
controls:0.41%
—
—
—
—
—
—
—
—
cases:2.59%
controls:1.94%
—
5
10
241
2450
—
—
—
—
5
38
188
1921
Calculus of gallbladder without cholecystitis
K80.2 [45552951]
9.3e-01
-1.0e+50
—
—
—
—
-1.0e+50
cases:2.03%
controls:0.81%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
5
20
241
2440
0
7
246
2453
—
—
—
—
0
15
193
1944
solifenacin; oral
G04BD08 [21602641]
—
—
—
—
—
1.5e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:2.49%
controls:0.58%
cases:3.63%
controls:1.28%
—
—
—
—
—
6
14
235
2395
7
25
186
1934
Borrelia burgdorferi IgM Ab [Units/volume] in Serum
7818-8 [3008230]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.11%
controls:0.82%
—
—
—
—
—
—
6
16
187
1943
Proctoscopy
UJG02 [2001305126]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
0
6
246
2454
—
—
—
—
—
0
5
193
1954
Screening for malignant neoplasm of prostate
444822002 [40481096]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
246
2454
—
—
—
—
—
—
Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection
92695-6 [37019628]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
246
2453
—
—
—
—
—
—
Hypersensitivity skin testing
268377001 [4147813]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
0
10
246
2450
—
—
—
—
—
0
6
193
1953
Neoplasm of uncertain or unknown behaviour: Skin
D48.5 [45586113]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.87%
—
—
—
—
—
—
5
17
188
1942
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
—
—
-1.0e+50
—
-1.0e+50
7.4e-01
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
cases:0.00%
controls:0.24%
cases:2.07%
controls:1.00%
—
—
—
—
0
5
246
2455
—
0
6
246
2451
5
24
236
2385
—
fluticasone furoate; nasal
R01AD12 [21605053]
6.0e-01
6.2e-01
—
—
—
1.0e+00
3.7e-01
cases:8.94%
controls:5.12%
cases:4.07%
controls:2.24%
—
—
—
—
—
—
cases:5.39%
controls:1.99%
cases:7.25%
controls:5.10%
22
126
224
2334
10
55
236
2405
—
—
—
13
48
228
2361
14
100
179
1859
Presence of dental prosthetic device (complete)(partial)
Z97.2 [45542503]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
246
2454
—
—
—
—
—
—
Tooth fracture UNS
S02.59 [2000503623]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
—
—
Acute prostatitis
N41.0 [45563017]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
8
193
1951
Contusion of toe(s) without damage to nail
S90.1 [45550695]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
—
—
econazole
D01AC03 [21601922]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.57%
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
0
14
246
2446
0
5
246
2455
—
—
—
—
—
Epstein Barr virus Ab [Presence] in Serum
49178-7 [3048929]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
193
1953
Nonorganic insomnia
F51.0 [45552492]
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.07%
controls:0.37%
—
—
—
—
—
—
—
5
9
236
2400
—
semaglutide; oral, parenteral
A10BJ06 [1501778]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
Oxygen saturation in Capillary blood
2709-4 [3021901]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
0
7
246
2453
—
—
—
—
0
9
193
1950
Vacuum treatment of wound
TQW11 [2001310078]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
193
1953
Aorto-coronary venous bypass with three distal anastomoses
FNC30 [2001303031]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
246
2447
—
—
—
—
—
—
Benign neoplasm: Sigmoid colon
D12.5 [45552326]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
246
2445
—
—
—
—
—
—
Hypo-osmolality and hyponatraemia
E87.1 [45542779]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
0
5
246
2455
—
—
—
0
6
241
2403
—
tinzaparin; parenteral
B01AB10 [21600981]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.11%
controls:0.97%
—
—
—
—
—
—
6
19
187
1940
Plastic operation of joint cartilage of knee
NGF35 [2001308135]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
246
2454
—
—
—
—
—
—
Calculus of bile duct without cholangitis or cholecystitis
K80.5 [45572234]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
0
5
246
2455
—
—
—
—
—
0
5
193
1954
Laparoscopic dissection of iliac lymph nodes
PJD64 [2001309643]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:4.98%
controls:0.00%
—
—
—
—
—
—
—
12
0
229
2409
—
Unspecified privation
X57 [45756410]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
246
2452
—
—
—
—
—
—
risperidone; oral, parenteral
N05AX08 [21604559]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
246
2455
—
0
9
246
2448
—
—
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
281 [2001600213]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
193
1954
scopolamine; oral, parenteral
N05CM05 [21604666]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
193
1954
Malignant tumor of the rectum invasive carcinoma
C20.91 [2000500574]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.20%
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
0
6
246
2454
0
5
246
2455
0
5
246
2455
—
—
—
—
triamcinolone; nasal
R01AD11 [21605052]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
9
193
1950
Cardiac arrhythmia, unspecified
I49.9 [45581778]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
0
7
246
2453
—
—
—
—
—
azathioprine; oral, parenteral
L04AX01 [21603927]
—
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.31%
—
—
0
5
246
2455
—
—
0
6
241
2403
0
6
193
1953
Teeth/gum symptom/complaint
D19 [2002000318]
6.2e-01
—
-1.0e+50
—
—
—
7.1e-01
cases:3.66%
controls:1.99%
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
cases:8.29%
controls:4.24%
9
49
237
2411
—
0
5
246
2455
—
—
—
16
83
177
1876
Human bocavirus DNA [Presence] in Specimen by NAA with probe detection
62424-7 [40765161]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
246
2454
—
—
—
—
—
—
Other administrative function
SPAT1281 [2001700382]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
0
7
246
2453
—
—
—
—
—
Pain in limb
M79.6 [45587063]
6.1e-01
4.2e-01
—
—
—
5.0e-01
4.3e-01
cases:7.32%
controls:4.11%
cases:3.66%
controls:2.44%
—
—
—
—
—
—
cases:3.32%
controls:2.03%
cases:10.36%
controls:6.99%
18
101
228
2359
9
60
237
2400
—
—
—
8
49
233
2360
20
137
173
1822
Deposits [accretions] on teeth betel
K03.65 [2000502690]
-2.0e-02
-1.0e+50
-1.0e+50
—
—
—
—
cases:2.03%
controls:2.07%
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
5
51
241
2409
0
12
246
2448
0
5
246
2455
—
—
—
—
Oral and dental health check by dental hygienist or dental assistant
SAB02 [2001310280]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
—
—
Malignant tumor of the caecum invasive carcinoma
C18.01 [2000500535]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
—
—
Bicarbonate [Moles/volume] in Venous blood
14627-4 [3027273]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
0
9
241
2400
—
Norovirus RNA [Presence] in Stool by NAA with probe detection
7974-9 [3008909]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
0
7
246
2453
—
—
—
—
0
6
241
2403
—
Other and unspecified intestinal obstruction
K56.6 [45562499]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
6
246
2454
—
—
—
—
—
Asthma, unspecified
J45.9 [45562456]
-1.1e-01
—
—
1.0e+50
-1.0e+50
8.8e-01
7.4e-01
cases:2.44%
controls:2.72%
—
—
—
—
cases:2.44%
controls:0.00%
cases:0.00%
controls:0.20%
cases:3.73%
controls:1.58%
cases:6.74%
controls:3.32%
6
67
240
2393
—
—
6
0
240
2460
0
5
246
2452
9
38
232
2371
13
65
180
1894
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
1.8e-01
-1.1e-01
—
—
—
7.9e-02
3.1e-01
cases:16.26%
controls:13.94%
cases:4.07%
controls:4.51%
—
—
—
—
—
—
cases:4.56%
controls:4.23%
cases:15.54%
controls:11.94%
40
343
206
2117
10
111
236
2349
—
—
—
11
102
230
2307
30
234
163
1725
other preparations, combinations; ointment
C05AX03 [21601631]
-4.3e-02
9.7e-01
—
—
—
—
4.5e-01
cases:2.85%
controls:2.97%
cases:2.85%
controls:1.10%
—
—
—
—
—
—
—
—
cases:5.18%
controls:3.37%
7
73
239
2387
7
27
239
2433
—
—
—
—
10
66
183
1893
pilocarpine; lamella, ointment
S01EB01 [21603680]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
—
—
Intraoperative use of conventional X-ray imaging
ZXM10 [2001311446]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.46%
0
7
246
2453
—
—
—
—
0
5
241
2404
0
9
193
1950
Excision of lesion of gingiva
ECA30 [2001301959]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
—
—
Disorientation, unspecified
R41.0 [45558469]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
0
7
246
2453
—
—
—
—
—
Other specified anaemias
D64.8 [45595771]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
8
193
1951
Functional dysphonia
R49.01 [2000503597]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
246
2451
—
—
—
—
—
—
Acute conjunctivitis, unspecified
H10.3 [45566958]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
246
2449
—
—
—
—
—
—
Other investigative procedure of eye
XCW99 [2001301491]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
0
17
246
2443
—
—
—
0
18
241
2391
—
Chronic gastritis, unspecified
K29.5 [45562484]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
193
1953
Other leisure activity accident
Y94.8 [2000503731]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
193
1953
Chronic glaucoma with open ventricular angle
H40.13 [2000502335]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
0
6
246
2451
—
—
Unstable angina
I20.09 [2000502389]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
0
10
246
2450
—
—
—
—
—
Normal-pressure hydrocephalus
G91.2 [45547765]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
0
9
246
2451
—
—
—
—
—
0
5
193
1954
Conjunctivitis, unspecified
H10.9 [45591253]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
—
Nontoxic multinodular goitre
E04.2 [45576425]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
—
—
Erythrocytes [#/area] in Urine sediment by Automated count
46419-8 [3048402]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
193
1953
Epicardial ultrasonography
XFE00 [2001303343]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.65%
cases:0.00%
controls:0.33%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.56%
0
16
246
2444
0
8
246
2452
—
—
—
0
7
241
2402
0
11
193
1948
INR in Blood by Coagulation assay
34714-6 [3032080]
-4.6e-03
5.5e-02
3.2e-01
—
2.2e-01
5.6e-03
8.0e-02
cases:9.76%
controls:9.80%
cases:6.50%
controls:6.18%
cases:3.66%
controls:2.68%
—
—
cases:3.66%
controls:2.97%
cases:7.47%
controls:7.43%
cases:17.62%
controls:16.49%
24
241
222
2219
16
152
230
2308
9
66
237
2394
—
9
73
237
2384
18
179
223
2230
34
323
159
1636
Examination of ears and hearing
Z01.1 [45547279]
4.2e-02
—
—
—
—
—
—
cases:2.03%
controls:1.95%
—
—
—
—
—
—
—
—
—
—
—
—
5
48
241
2412
—
—
—
—
—
—
Left sided colitis
K51.5 [45533604]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
0
7
246
2453
—
—
—
—
0
9
193
1950
Lactate [Moles/volume] in Arterial blood
2518-9 [3018405]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
6
246
2454
—
—
—
—
—
timolol, combinations
S01ED51 [21603705]
—
—
-1.0e+50
—
—
-3.6e-01
-1.4e-02
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
cases:2.07%
controls:2.95%
cases:3.63%
controls:3.68%
—
—
0
18
246
2442
—
—
5
71
236
2338
7
72
186
1887
Fungus identified in Specimen by Culture
580-1 [3000494]
—
—
-1.0e+50
—
—
—
7.0e-01
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:3.63%
controls:1.84%
—
—
0
6
246
2454
—
—
—
7
36
186
1923
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
6.4e-01
1.1e+00
—
—
—
—
—
cases:4.07%
controls:2.20%
cases:3.25%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
10
54
236
2406
8
26
238
2434
—
—
—
—
—
Doppler ultrasound examination of heart
FM1DE [2001303299]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.68%
—
—
—
—
—
—
0
33
193
1926
Percutaneous insertion of coronary artery stent
FN1YT [2001303064]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:1.68%
—
—
—
—
—
0
9
241
2400
0
33
193
1926
nedocromil; inhalant
R03BC03 [21603299]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
—
—
Angina pectoris, unspecified
I20.9 [45562339]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
193
1954
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
0
6
246
2454
—
—
—
—
roxithromycin; oral
J01FA06 [21602974]
-4.5e-01
—
—
—
—
—
9.1e-01
cases:2.44%
controls:3.78%
—
—
—
—
—
—
—
—
—
—
cases:5.18%
controls:2.14%
6
93
240
2367
—
—
—
—
—
10
42
183
1917
General and Unspecified, Result test/procedure
A60 [2002000194]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
0
5
246
2455
—
—
—
—
—
0
12
193
1947
Spontaneous ecchymoses
R23.3 [45539326]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
7
193
1952
sulfadiazine and trimethoprim
J01EE02 [21602962]
—
—
—
—
—
1.9e+00
6.6e-01
—
—
—
—
—
—
—
—
—
—
cases:2.49%
controls:0.37%
cases:4.15%
controls:2.19%
—
—
—
—
—
6
9
235
2400
8
43
185
1916
doxepin; oral, parenteral
N06AA12 [21604699]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
8
193
1951
Tinea unguium
B35.1 [45590850]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
7
241
2402
—
Other healthcare associate professional
Z3229 [2001311561]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
—
0
19
246
2441
—
—
—
—
—
Gonarthrosis [arthrosis of knee]
M17 [45601350]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
11
246
2449
—
—
—
—
—
Haemorrhage of anus and rectum
K62.5 [45596339]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.11%
controls:0.66%
—
—
—
—
—
—
6
13
187
1946
Telephone, letter or other consultation without direct patient contact
ZY020 [2001311600]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.85%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
0
21
246
2439
0
7
246
2453
—
—
—
—
—
Sciatica
M54.3 [45586994]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
246
2446
—
—
—
—
—
—
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
-1.3e-02
-3.6e-02
—
—
—
-2.0e-01
2.5e-02
cases:19.92%
controls:20.12%
cases:11.38%
controls:11.75%
—
—
—
—
—
—
cases:10.37%
controls:12.41%
cases:34.72%
controls:34.15%
49
495
197
1965
28
289
218
2171
—
—
—
25
299
216
2110
67
669
126
1290
Segmented neutrophils/Leukocytes in Blood
26505-8 [3017354]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
0
11
246
2449
—
—
—
—
0
5
241
2404
—
Cerebral aneurysm, nonruptured
I67.1 [45538401]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
246
2455
—
—
—
—
—
—
Glucose tolerance 2 hours panel - Serum or Plasma
72171-2 [43054914]
—
-1.0e+50
—
—
—
-1.0e+50
7.2e-01
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:2.59%
controls:1.28%
—
0
6
246
2454
—
—
—
0
8
241
2401
5
25
188
1934
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]
-6.7e-01
—
—
—
—
—
1.0e+50
cases:2.44%
controls:4.67%
—
—
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.00%
6
115
240
2345
—
—
—
—
—
5
0
188
1959

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
61
224
3.29
13.31
6.7
4.1
7.31
7.35
ph
0.83
39
165
44
179
2.77
7.79
2.2
2.1
0.00
0.00
estimate
—
5
33
31
112
3.02
6.77
5.7
4.8
23.65
25.12
mmol/l
1.78
26
105
203
1655
2.27
5.85
9.1
6.2
2.96
2.89
ug/l
0.03
174
1468
50
259
2.17
5.17
2.6
3.0
4.55
5.36
e9/l
0.38
31
218
37
184
2.19
4.21
4.1
3.6
—
—
—
0
0
32
152
2.27
4.06
5.8
3.9
—
—
—
0
0
30
140
2.30
3.96
1.9
2.0
1.91
2.12
ug/l
0.06
21
119
150
1178
1.70
3.91
4.3
3.4
56.15
63.86
u/l
0.57
137
1097
134
1025
1.67
3.83
2.4
2.3
101.22
89.75
pmol/l
1.52
72
607
39
209
2.03
3.66
5.7
3.8
7.41
7.42
ph
0.23
28
169
39
214
1.98
3.43
5.7
3.8
4.82
5.11
kpa
1.52
34
208
102
755
1.60
3.15
2.5
2.4
—
—
—
0
0
11
30
3.79
3.12
2.6
2.9
—
—
—
0
0
21
96
2.30
2.93
2.4
3.6
1.22
3.51
ratio
1.41
15
52
35
579
0.54
2.93
2.5
3.7
—
—
—
0
0
101
757
1.57
2.91
2.6
2.7
—
—
—
0
0
29
152
2.03
2.90
3.0
3.3
—
—
—
0
0
66
915
0.62
2.79
9.9
13.3
0.00
0.00
e9/l
0.63
50
747
98
740
1.54
2.68
5.6
5.8
—
—
—
0
0
35
203
1.84
2.62
4.6
2.8
—
—
—
0
0
107
827
1.52
2.62
4.3
4.7
—
—
—
0
0
140
1145
1.51
2.61
9.6
8.0
1.19
1.20
mmol/l
0.18
115
1001
11
36
3.15
2.60
2.2
2.4
0.82
1.26
g/24h
—
6
20
129
1045
1.49
2.47
8.4
7.2
1.20
1.20
mmol/l
0.27
110
959
189
1664
1.58
2.39
4.8
4.3
2.01
2.09
mu/l
0.29
155
1462
20
98
2.13
2.39
2.4
1.9
—
—
—
0
0
6
172
0.33
2.38
8.2
3.8
—
—
—
0
0
121
978
1.47
2.29
5.6
6.1
0.63
0.58
%
0.38
106
920
121
978
1.47
2.29
5.5
6.0
2.58
2.88
%
0.89
106
917
6
13
4.70
2.28
2.8
1.3
—
—
—
0
0
121
982
1.46
2.22
5.7
6.1
9.30
9.43
%
0.18
106
918
113
906
1.46
2.21
3.5
3.6
1643.73
1753.13
ng/l
0.16
92
798
159
1361
1.47
2.20
4.8
5.7
6.64
7.01
mmol/l
2.11
153
1319
24
410
0.54
2.19
5.3
5.1
—
—
—
0
0
120
975
1.45
2.18
5.3
6.0
61.07
59.76
%
0.63
106
929
199
1788
1.58
2.15
5.6
5.6
4.09
4.13
mmol/l
0.23
164
1626
123
1008
1.44
2.11
2.9
3.0
—
—
estimate
—
0
0
202
1830
1.57
2.00
6.4
6.4
2.36
2.37
mmol/l
0.08
170
1654
130
1084
1.42
1.99
5.4
6.0
0.20
0.21
e9/l
0.40
106
941
12
51
2.42
1.98
1.5
1.3
—
—
—
0
0
118
968
1.42
1.98
4.9
3.5
0.74
0.83
ug/l
0.77
90
694
205
1866
1.58
1.96
24.6
21.4
29.75
30.50
mg/l
0.11
182
1637
197
1782
1.52
1.89
6.1
5.5
1.31
1.30
mmol/l
0.15
165
1604
120
1407
0.71
1.86
30.9
28.5
332.58
332.66
g/l
0.03
120
1400
93
738
1.42
1.85
1.9
1.8
15.93
18.73
nmol/l
1.18
72
606
13
60
2.23
1.81
3.3
4.1
—
—
—
0
0
39
560
0.64
1.79
4.9
3.7
0.00
0.15
estimate
0.58
13
183
118
981
1.39
1.78
4.9
4.8
33.54
47.51
ng/l
1.16
99
821
199
1815
1.50
1.72
6.6
5.9
6.06
6.22
mmol/l
1.22
163
1627
63
471
1.45
1.72
1.8
1.8
1046.32
1145.48
nmol/l
0.31
41
366
211
1949
1.57
1.71
30.5
26.4
139.51
139.60
mmol/l
0.19
204
1924
105
862
1.38
1.68
3.1
3.0
185.37
192.13
ug/l
0.09
92
793
211
1951
1.56
1.68
30.7
26.6
4.03
4.06
mmol/l
0.66
204
1927
213
1974
1.57
1.67
35.9
32.1
91.76
92.24
fl
0.69
208
1956
213
1975
1.57
1.66
35.9
32.0
30.45
30.70
pg
0.94
208
1956
213
1975
1.57
1.66
36.0
32.2
230.07
223.80
e9/l
0.73
204
1940
213
1975
1.57
1.66
36.0
32.2
7.32
7.18
e9/l
0.42
203
1936
213
1975
1.57
1.66
36.0
32.1
4.43
4.44
e12/l
0.07
201
1935
213
1975
1.57
1.66
36.1
32.4
133.75
134.81
g/l
0.38
208
1955
213
1975
1.57
1.66
36.2
32.9
39.92
39.99
%
0.06
208
1954
118
991
1.37
1.63
5.6
6.2
23.05
24.32
%
0.65
108
937
212
1966
1.55
1.62
32.9
29.1
99.25
93.88
umol/l
1.09
206
1950
15
78
1.98
1.58
1.1
1.3
—
—
—
0
0
13
64
2.09
1.57
2.3
1.3
—
—
—
0
0
8
33
2.47
1.55
1.1
1.3
—
—
—
0
0
124
1056
1.35
1.54
5.3
5.9
0.65
0.65
e9/l
0.06
104
895
36
245
1.55
1.54
4.5
3.3
65.39
66.11
g/l
0.23
29
222
6
21
2.90
1.51
3.2
2.3
—
—
—
0
0
124
1061
1.34
1.47
5.3
5.9
0.04
0.04
e9/l
0.29
103
904
125
1073
1.33
1.44
5.4
6.1
1.63
1.81
e9/l
1.22
103
943
189
1728
1.40
1.43
4.9
4.7
1.24
1.28
mmol/l
0.33
151
1548
176
1591
1.37
1.43
9.8
9.3
79.67
83.98
u/l
0.54
169
1512
41
295
1.47
1.36
2.2
2.5
66.95
64.65
e9/l
0.21
33
229
9
172
0.51
1.35
4.3
4.3
1.23
1.21
mmol/l
—
9
151
143
1261
1.32
1.33
21.0
19.5
1.33
1.39
inr
0.65
117
1071
39
281
1.46
1.29
2.0
1.8
—
—
—
0
0
8
37
2.20
1.22
1.5
2.5
—
—
—
0
0
5
19
2.66
1.22
1.0
1.1
—
—
—
0
0
201
1875
1.39
1.19
23.2
19.7
—
—
—
0
0
51
393
1.38
1.17
2.8
2.7
21.63
22.53
%
0.15
46
366
52
403
1.37
1.15
3.8
3.5
2.29
0.62
e6/l
0.64
27
235
18
111
1.67
1.15
1.0
1.1
—
—
—
0
0
74
606
1.32
1.14
3.6
3.3
375.39
380.02
umol/l
0.15
62
525
39
288
1.42
1.14
2.4
2.5
10.67
12.60
nmol/l
0.59
29
247
8
40
2.03
1.13
1.1
1.2
—
—
—
0
0
54
424
1.35
1.11
2.6
2.7
2.12
2.19
g/l
0.53
48
392
27
187
1.50
1.09
1.7
1.5
—
—
—
0
0
30
213
1.46
1.08
1.2
1.2
226.67
382.11
titre
—
6
38
132
1174
1.27
1.06
7.1
10.2
4.90
4.44
e9/l
1.16
114
1021
24
164
1.51
1.04
1.9
1.6
—
—
—
0
0
191
1781
1.32
1.03
8.2
7.8
40.22
41.10
mmol/mol
0.61
152
1641
17
108
1.62
0.99
1.7
1.3
—
—
—
0
0
33
245
1.40
0.95
2.0
2.5
4.81
7.15
ug/l
0.74
23
216
39
299
1.36
0.94
1.3
1.4
—
—
—
0
0
56
456
1.29
0.90
2.8
2.7
11.14
12.43
umol/l
0.56
50
424
6
29
2.09
0.90
1.2
1.0
—
—
—
0
0
33
248
1.38
0.89
1.3
1.3
13.44
39.84
iu/ml
—
7
69
6
30
2.02
0.87
1.3
1.1
—
—
—
0
0
78
665
1.25
0.87
2.2
2.2
3.20
2.99
mg/l
0.27
65
576
6
32
1.90
0.82
1.0
1.2
—
—
—
0
0
21
148
1.46
0.81
1.4
1.4
1.88
1.53
g/l
0.67
16
135
57
472
1.27
0.81
4.7
4.0
—
0.44
—
0
9
69
804
0.80
0.80
4.9
4.3
0.00
0.05
estimate
1.32
13
206
35
444
0.75
0.80
1.7
1.7
1.34
1.74
mg/l
0.52
25
362
30
227
1.37
0.79
1.3
1.3
1.14
18.83
u/ml
—
8
76
0
27
0.00
0.78
0.0
2.1
—
492.50
—
0
16
94
827
1.22
0.77
4.1
3.7
6.10
6.17
ph
0.25
50
460
203
1932
1.28
0.77
15.1
13.6
24.85
26.04
u/l
0.38
189
1877
29
221
1.35
0.74
2.1
1.6
—
—
—
0
0
46
376
1.27
0.72
2.1
2.3
1.78
1.71
%
0.21
39
336
5
28
1.80
0.66
1.0
1.0
—
—
—
0
0
72
628
1.21
0.64
3.6
3.4
—
—
—
0
0
13
88
1.50
0.62
1.1
1.3
—
—
—
0
0
17
123
1.41
0.59
2.1
2.5
—
—
—
0
0
0
22
0.00
0.59
0.0
1.5
—
—
—
0
0
140
1301
1.18
0.59
3.3
3.3
15.48
15.03
pmol/l
1.25
113
1136
114
1042
1.17
0.59
4.4
4.1
0.00
0.00
estimate
-0.00
15
243
113
1036
1.17
0.56
5.4
5.6
34.10
34.17
g/l
0.04
99
976
116
1066
1.17
0.55
4.8
4.1
0.00
1.33
estimate
0.51
14
229
32
262
1.25
0.52
1.3
1.5
—
—
—
0
0
80
722
1.16
0.48
1.8
2.0
1.28
1.26
mmol/l
0.09
65
568
114
1056
1.15
0.47
4.8
4.1
0.00
0.01
estimate
0.50
15
248
20
156
1.31
0.47
3.0
4.3
23.34
23.73
mmol/l
0.42
20
156
10
69
1.47
0.45
26.4
13.9
—
—
—
0
0
5
31
1.63
0.43
1.0
1.1
—
—
—
0
0
8
58
1.39
0.42
1.0
1.1
—
—
—
0
0
5
33
1.53
0.41
4.6
1.5
90.52
88.82
%
—
5
33
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
2.2
—
—
—
0
0
0
18
0.00
0.40
0.0
2.3
—
508.33
—
0
12
81
741
1.14
0.40
2.2
4.0
2.32
2.33
mmol/l
0.09
66
663
9
67
1.36
0.38
1.4
1.7
—
—
—
0
0
65
588
1.14
0.37
6.5
6.5
—
—
—
0
0
5
80
0.62
0.36
2.6
3.8
1.64
1.59
mmol/l
—
5
75
75
814
0.89
0.35
4.7
3.6
101.50
71.91
mg/l
0.23
51
576
78
838
0.90
0.30
5.3
4.4
23.54
11.27
mg/mmol
0.45
52
567
7
57
1.23
0.29
1.1
1.1
—
—
—
0
0
28
245
1.16
0.26
5.3
9.8
—
—
—
0
0
27
236
1.16
0.25
1.2
1.3
—
—
—
0
0
27
236
1.16
0.25
3.2
2.9
0.36
0.41
e6/l
0.09
27
229
5
39
1.29
0.23
4.8
2.7
60.04
57.59
%
—
5
39
0
11
0.00
0.21
0.0
1.3
—
91.91
—
0
11
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
27.70
—
0
10
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
13
109
1.20
0.19
1.1
1.5
—
—
—
0
0
13
110
1.19
0.17
2.5
4.7
1.02
1.02
ratio
0.09
13
105
22
197
1.13
0.16
1.3
1.5
—
—
—
0
0
18
202
0.88
0.15
4.6
6.0
23.74
24.15
mmol/l
0.17
18
195
17
191
0.88
0.14
4.9
4.8
0.00
0.17
%
—
8
60
34
366
0.92
0.14
4.8
7.5
7.43
7.41
ph
0.97
22
217
18
198
0.90
0.11
4.1
4.4
0.89
0.88
%
—
9
74
49
467
1.06
0.10
5.8
4.5
1.02
1.02
kg/l
0.99
42
321
79
816
0.95
0.10
4.7
3.6
7.24
7.96
mmol/l
0.71
61
678
64
662
0.96
0.09
5.4
5.0
7.39
7.39
ph
0.17
40
483
6
56
1.07
0.08
7.2
4.3
—
—
—
0
0
23
246
0.93
0.08
3.2
3.2
5.55
4.38
kpa
0.61
23
235
84
818
1.04
0.08
5.1
3.7
66.08
179.31
e6/l
0.67
63
660
40
382
1.06
0.08
2.1
1.9
—
—
—
0
0
31
294
1.06
0.07
3.1
4.0
7.39
7.38
ph
0.32
18
173
65
631
1.04
0.07
4.6
4.2
0.00
0.01
estimate
0.50
14
214
27
257
1.06
0.05
1.4
1.3
—
—
—
0
0
32
333
0.96
0.05
1.5
1.2
2.08
1.31
u/ml
—
5
95
20
189
1.06
0.05
4.1
4.4
1.27
0.42
%
0.59
11
68
19
201
0.94
0.04
3.3
3.9
—
—
—
0
0
35
362
0.96
0.04
4.4
7.5
0.46
0.80
mmol/l
0.21
30
297
18
190
0.94
0.04
4.1
4.5
0.11
0.11
%
—
9
66
50
510
0.98
0.02
1.6
1.9
153846576.03
22717019.20
pmol/l
0.40
39
427
70
691
1.02
0.02
5.1
3.6
0.21
0.39
e6/l
1.17
48
541
31
316
0.98
0.00
1.8
1.4
2.40
3.02
g/l
1.04
18
189
29
291
1.00
0.00
3.0
4.0
5.43
5.74
kpa
1.11
29
278
87
871
1.00
0.00
5.9
4.2
78.53
177.11
e6/l
0.62
64
678
53
527
1.01
0.00
1.2
1.3
—
—
—
0
0
14
136
1.03
0.00
2.6
3.4
24.16
25.15
mmol/l
0.59
14
128
15
154
0.97
0.00
1.4
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
19.5
—
834.83
—
0
6
0
6
0.00
0.00
0.0
26.0
—
1257.83
—
0
6
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
4.5
—
6.87
—
0
6
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
5.0
—
54.20
—
0
5
0
7
0.00
-0.00
0.0
1.6
—
34.86
—
0
7
5
58
0.86
-0.00
1.2
1.6
18.80
31.89
g/l
—
5
52
0
5
0.00
-0.00
0.0
1.4
—
70.80
—
0
5
0
8
0.00
-0.00
0.0
1.0
—
15.91
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
1.19
—
0
5
0
7
0.00
-0.00
0.0
1.6
—
9.99
—
0
7
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
8
82
0.97
-0.00
2.0
1.8
38.00
47.88
nmol/l
—
8
75
0
5
0.00
-0.00
0.0
1.0
—
17.76
—
0
5
0
5
0.00
-0.00
0.0
2.2
—
2.20
—
0
5
6
60
1.00
-0.00
1.2
1.6
13.32
15.72
mg/l
—
6
53
9
99
0.91
-0.00
1.1
1.3
—
—
—
0
0
5
49
1.02
-0.00
1.2
1.3
644.00
1999.42
e6/l
—
5
31
0
8
0.00
-0.00
0.0
1.3
—
254.00
—
0
8

Mortality – FinRegistry

↥

Association

Association between endpoint CD2_BENIGN_PROSTATE and mortality.

Females

No data

Males

Parameter HR [95% CI] p-value
CD2_BENIGN_PROSTATE 1.364 [1.17, 1.6] < 0.001
Birth year 0.986 [0.98, 1.0] 0.004

During the follow-up period (1.1.1998 — 31.12.2019), 550 out of 1196 males with CD2_BENIGN_PROSTATE died.

Mortality risk

Mortality risk for people of age

years, who have CD2_BENIGN_PROSTATE.

N-year risk Females Males
1 No data 0.208%
5 No data 1.545%
10 No data 3.859%
15 No data 7.262%
20 No data 12.475%

Relationships between endpoints

↥

Index endpoint: CD2_BENIGN_PROSTATE – Benign neoplasm: Prostate

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data